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ABSTRACT 
 
Background: In Palestine, prostate cancer accounts for 5.3% of all cancer cases.  The age-
standardized incidence rate is 20 per 100,000 populations.  It has a mortality of 4.8% of all 
cancer in year 2010.  Literature shows that congenital factors, lifestyle factors and 
environmental exposures were found to determine the risk of its occurrence.  
In Palestine, there is no screening program for prostate cancer. Also, no study investigated 
the risk/protective factors for this serious disease.  Therefore, we planned this study to be a 
baseline study for decision makers to help in planning for a national strategy that can help 
in preventing this cancer and/or its complications.   
Aim and objectives: This study aimed to identify the determinants of prostate cancer in 
the south area of West bank.  Its objectives were to determine the associations between the 
various lifestyles, socio-demographic, family history of malignancy, and patients' health 
status with the risk of developing prostate cancer. 
Study methodology:  This retrospective case-control study investigated 60 prostate cancer 
cases (study cases), and 60 study controls. All prostate cancer cases attending Beit Jala 
outpatients' cancer clinic and the oncology department during the study period were 
approached with similar number of controls from the same age group (non-cancer/ no 
urology patients) attending the same hospital but for other reasons. The diagnosis of 
prostate cancer of each case was ascertained by his medical record. All the study controls 
underwent a PSA test as an indicator of prostate activity that reflects no cancer presence. 
Both study cases and control group were interviewed while waiting in the outpatient clinic 
assembly of BJGH. Part of the study cases were interviewed in the day care unit while 
receiving their prescribed chemotherapy. A structured questionnaire was used to collect 
information about the Sociodemographic, lifestyle factors, health status of the participants, 
and there family history of malignancy. Cases medical records were reviewed to extract the 
confirmation of prostate cancer diagnosis, the date of diagnosis, and to get the baseline 
PSA test results. 
Statistical Analysis: SPSS was used for data entry and analysis. Continuous variables 
were compared between the study cases and control group using T-test. Pearsson chi-
square test or fisher’s exact test were used for comparison of categorical variables between 
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the two groups (study cases and control group). Conditional logistic regression models 
were used in the multivariate analysis.  
Results: Analysis of study cases data showed that the mean age of the participants was 
67.7 ±9.5 (mean± SD), and 83.3% of the study cases were older than 60 years of age. Of 
them, 73.3% were married, and 46.7% had 5- 8 children. Of the study cases 13.3% was 
illiterate, and 16.7% had completed higher education and 58.3% lived in urban areas.  
Also, 53.3% were unemployed, 46.7% of those working in the past 10 years had office 
work and 68.3% had a monthly income ≤3000 NIS.  
On the other hand, analysis of control group data showed that the mean age of the 
participants was 65.7 ±10 (mean± SD), and 71.7% of the control group were older than 60 
years of age. Of them, 86.7% were married, and 60% had 5- 8 children. Of the control 
group 11.7% was illiterate, and 11.7% had completed higher education and 48.3% lived in 
urban areas.  Also, 55% were unemployed, 45% of those working in the past 10 years had 
office work and 88.3% had a monthly income ≤3000 NIS 
The multivariate analysis showed that married men are at lower risk for prostate cancer 
development by five folds. Also low family monthly income increased the risk by ten folds 
to have prostate cancer.  Moreover, weekly consumption of cruciferous vegetables 
(AOR=0.15), homemade cheese (AOR=0.10), and processed meat (AOR=0.19) showed a 
significant inverse association with prostate cancer occurrence. In addition, type 2 diabetes 
mellitus and cardiovascular diseases appeared to increase the risk of prostate cancer by 
three folds and seven folds, respectively.  
Conclusion: This is the first study that deals with prostate cancer epidemiology in the 
West Bank. The study yielded important results regarding the determinants of prostate 
cancer in Palestine. We were able to show how patients' lifestyle factors determined the 
risk/protection of prostate cancer in Palestine. These findings stress on the fact that 
modification of lifestyle might play an important role in this disease prevention.  
This study recommends an establishment of a national program for early detection of 
prostate cancer. Also, give attention to the modifiable lifestyle factors that increase or 
decrease the risk of this type of cancer among the Palestinian population. This study 
stimulates the conduction of more specified studies in the field of male cancers in 
Palestine. 
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ستعادية دراسة الحالات و : دراسة افي جنوب الضفة الغربية العوامل المرتبطة بمرض سرطان غدة البروستات
 .الشواهد
 اعداد: ياسر قاسم
 اشراف د. نهى الشريف
 ملخص الدراسة
من إجمالي حالات السرطان المسجلة في  %5.3: يشكل مرض سرطان غدة البروستات ما نسبته اسةخلفية الدر
 %4.8ب حالة لكل مئة ألف من السكان. ويساهم مرض سرطان غدة البرستات 20 الوقوعفلسطين. كما ويشكل معدل 
عوامل البيئية لها علاقة . وقد وجد أن عوامل نمط الحياة والفي فلسطين من حالات الوفيات بسبب مرض السرطان
 بحدوث هذا النوع من السرطان.
لا يوجد في فلسطين برنامج للكشف المبكر عن مرض سرطان غدة البرستات. وكذلك لا يوجد أي دراسة في فلسطين 
الفلسطيني. لذلك فقد  عتهدف للكشف عن العوامل المساعدة على حدوثه أو العوامل التي قد تقي من حدوثه في المجتم
اعدة ارتكاز لصناع القرار لمساعدتهم في التخطيط لمنهجية وطنية تساعد على منع قنا بعمل هذه الدراسة لتكون قم
 حدوث هذا المرض أو الحد من مضاعفاته.
. كما في مناطق جنوب الضفة الغربيةرفة محددات مرض سرطان البروستات : هدفت هذه الدراسة لمعأهداف الدراسة
قة بين نمط الحياة والعوامل الاجتماعية والسكانية وتاريخ العائلة المرضي والوضع الصحي العام هدفت إلى معرفة العلا
 وخطر الإصابة بمرض سرطان غدة البرستات.
حالة مصابة بمرض سرطان  20دراسة الحالات و الشواهد). حيث تم إشراك (: دراسة استعادية منهجية الدراسة
بة بهذا المرض. المشاركون في هذه الدراسة كانوا جميعهم من المرضى حالة مقارنة غير مصا 20البروستات و
ة. خضع فالمراجعين لعيادات مستشفى بيت جالا الحكومي أو من المرضى الذين تم إدخالهم لأقسام المستشفى المختل
 -اتوهو فحص يستخدم عادة للكشف عن سرطان غدة البروست-  ASPكافة المشاركين من مجموعة المقارنة لفحص 
ثناء الانتظار في قاعة أ ت مقابلتهمللتأكد من خلوهم من هذا المرض. كلا المجموعتين ( المصابين وغير المصابين) تم
 الانتظار في العيادات الخارجية لمستشفى بيت جالا الحكومي أو أثناء تلقيهم للعلاج الكيميائي في وحدة العناية اليومية. 
صا لهذه الدراسة لجمع معلومات عن الحالة الاجتماعية السكانية ونمط الحياة والحالة وقد تم استخدام استبانة أعدت خصي
الصحية العامة والتاريخ العائلي لمرض السرطان من المشاركين في هذه الدراسة. كما تم تفحص الملف الطبي للمريض 
 عند التشخيص.  ASPللتأكد من التشخيص وتاريخ التشخيص و نتيجة فحص 
. ففي المرحلة الأولى،  تم حساب  MBI-SSPS: تم إدخال جميع البيانات وتحليلها باستخدام برنامجحص اييالتحليل الإ
بيانية، أما في المرحلة الثانية تم فحص العلاقة  التكرارات لجميع المتغيرات، وقد عرضت البيانات في جداول وأشكال
)، كما تم حساب فحص 1.0< P( الاحصائية لالةبين سرطان غدة البروستات و عوامل الإختطار عند مستوى الد
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بين حالات الدراسة والمجموعة الضابطة، كذلك تم حساب  ASPلرصد اختلاف مستويات  )tset-t(العامل المستقل  
) في تحليل وحيد المتغير 1.0< P( لجميع المتغيرات عند الدلالة الاحصائية المتعدد اللوجيستي الانحدار نموذج
 ).%20ة الترجيح ودرجة الثقة (للحصول على نسب
عاما بانحراف معياري بلغ  00: بينت نتائج الدراسة أن معدل أعمار المشاركين في هذه الدراسة كان النتايج الرييسية
من المشاركين كانوا متزوجين وكانت أعمارهم عند  %24عاما.  20من المشاركين أكبر من  %99. وقد كان 9.0
 اانوك %02أولاد وأن  4-3من المشاركين كان عندهم   %53كما أظهرت الدراسة أن  عاما. 30و  20الزواج بين 
من المشاركين كانوا  %83كانوا من سكان المدن. وكشفت الدراسة أن  %53قد أنهوا التعليم الجامعي و %82أميين و 
ة. وكان الدخل الشهري ل كانوا يعملون في وظائف مكتبية خلال العشرة أعوام الأخير %4.38من غير العاملين وأن 
 .قلشيكل أو أ 2225من المشاركين  %49
زوجين كانوا أقل عرضة لخطر الإصابة متوقد أظهرت تنائج تحليل نموذج الانحدار اللوجستي المتعدد أن الرجال ال
زيد بمرض سرطان غدة البروستات بخمس مرات مقارنة بغير المتزوجين. كذلك تبين أن الدخل الشهري المنخفض قد ي
من الدخل المرتفع. أما بالنسبة للعوامل الغذائية فقد تبين أن كلا من الخضروات  أكثر من خطر الإصابة عشر مرات
الصليبية و الجبنة البلدية و اللحوم المصنعة قد تقلل من خطر الإصابة  بمرض سرطان غدة البروستات. ومن الناحية 
وع الثاني وأمراض القلب و الشرايين قد تزيد من احتمال حدوث الصحية للمشاركين فقد تبين أن مرض السكري الن
 مرات على التوالي. 8و  5مرض سرطان غدة البروستات 
: تعتبر هذه الدراسة الأولى في فلسطين التي تتطرق لموضوع مرض سرطان غدة البروستات من حيث الخاتمة
ذا المرض بين رجال المجتمع الفلسطيني. حيث المحددات. وقد تمخضت هذه الدراسة عن نتائج هامة تخص محددات ه
تبين أن عوامل نمط الحياة للمشاركين في هذه الدراسة حددت مدى احتمال الإصابة أو الحماية من هذا المرض. وهذه 
 النتائج تؤكد أن عوامل نمط الحياة التي يمكن التحكم بها تلعب دورا هاما في الوقاية من هذا المرض.
بضرورة تفعيل برنامج وطني للكشف المبكر عن مرض سرطان غدة البروستات. كما توصي  وتوصي هذه الدراسة
أيضا بأهمية الالتفات الى عوامل نمط الحياة التي يمكن التحكم بها والتي قد تحد من انتشار هذا المرض بين الرجال في 
ا وتفصيلا في هذا المجال لزيادة القدرة المجتمع الفلسطيني. وتحث هذه الدراسة الباحثين على إجراء دراسات أكثر عمق
 على السيطرة على هذا المرض.  
VII 
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Chapter One: Introduction 
1.1 Background 
Prostate cancer has the highest prevalence of any nonskin cancer in the human body, with 
similar likelihood of neoplastic foci found within the prostates of men around the world 
regardless of diet, occupation, lifestyle, or other factors. Essentially all men with 
circulating androgens will develop microscopic prostate cancer if they live long enough 
(Bostwick et al., 2004). Prostate cancer is a disease of increasing significance worldwide. 
In many industrialized nations such as the United States, it is one of the most common 
cancers and among the leading causes of cancer deaths (Jemal et al., 2006). 
In developing countries prostate cancer is less common compared to developed countries, 
however its incidence and mortality has been on the rise (Delongchamps et al., 2007). In 
countries of the Middle-East, prostate cancer is already a problem, and the incidence rates 
in Arab countries are ranging from 4-30 per 100,000 men (Salim et al., 2009).  The 
prevalence in Palestine is 28.9/100,000, while in Jordan is 72.9 per/100,000, and in Israel 
is 15.5 per 100,000 (Sharaf, 2006). In Palestine, the prostate cancer accounts for 5.3% of 
all cancer cases, and its mortality is 4.8% of all cancer deaths during year 2010 (PHIC, 
2010).  
In many countries, prostate cancer screening programs for the early detection of the disease 
is done by using either PSA or the digital rectal examination. Early detection of prostate 
cancer using screening increases the probability of cure and decreases the mortality from 
prostate cancer (Villers et al., 2003). In the United States, approximately 90% of prostate 
cancers are detected by means of screening (Hoffman, 2011). But early results from two 
large, randomized, controlled trials of screening were inconsistent; an European study 
showed a modest decrease in prostate-cancer mortality, whereas a U.S. study showed no 
decrease in prostate-cancer mortality (Hoffman, 2011). In Palestine, there is no screening 
program for prostate cancer.  
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Prostate cancer can be prevented more easily than other types of cancers. However, there 
is no proven prostate cancer prevention strategy. But reducing the risk of prostate cancer 
is possible by making healthy choices, such as exercising and eating a healthy diet. In 
addition to changing lifestyle with healthy food and reducing dairy and calcium intake, 
taking certain drugs (5ARI) may prevent cancer development (Chung, 2010).  
Also, other factors such Lycopene, vegetables intake, and green tea consumption was 
shown to be protective factors that may decrease the risk of prostate cancer (Kamel et al., 
2006, Cohen et al., 2000, Kolonel et al., 2000, Gann et al., 1999, Bettuzzi et al., 2006, 
Wu and Yu, 2006). Moreover, avoiding risk factors such as smoking, being overweight 
and lack of exercise may help prevent prostate cancer (Gong et al., 2006, Hosseini et al., 
2010, Kamel et al., 2006, Putnam et al., 2000, Rodriguez et al., 1997, Tyagi et al., 2010). 
Increasing protective factors such as quitting smoking, eating a healthy diet and 
exercising may also help in preventing prostate cancer. However, in Palestine no study 
investigated the risk factors for prostate cancer.  
1.2 Study Problem 
Very few local researchers have been concerned with the determinants when discussing 
the epidemiology of prostate cancer. Early detection of prostate cancer indictors such as 
PSA testing which has been used in screening programs proved to be a good method of 
preventing cancer itself or progression of prostate cancer into more complicated cancer 
(Schroder et al., 2012).   
However, protecting men at risk for prostate problems, such as smokers, obese men, 
alcohol drinkers, physically inactive men and others, was proved to be a tool of 
prevention from cancer.  Therefore, it is very important to specify the factors that play a 
role as risk/protective factors among men in Palestine.  This data is not available in 
Palestine, which makes it a rich area for research.  Results of this research will be the 
baseline for any future plans in the area of prevention of prostate cancer; whether primary 
to avoid its occurrence or secondary such as screening for early detection. 
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1.3 Justification of the study 
Men health and its research is a neglected area in Palestine compared to women's health 
research although prostate cancer counts for 5.3% of all cancer cases, and located in the 
sixth rank among cancer types affecting Palestinian population, and the third among 
men(PHIC, 2010). Remarkably, the incidence rate in Palestine is higher than the 
surrounding countries. For example in Egypt the age-standardized incidence rate is 4.4 
per 100,000 populations (Baade et al., 2009,Salim et al., 2009). While in Jordan the age-
standardized incidence is 11.2 per 100,000 populations (Salim et al., 2009). In Palestine 
the age-standardized incident rate is 20 per 100,000 populations (Salim et al., 2009). 
Prostate cancer mortality in Palestine is 4.8% of all cancer deaths during 2010(PHIC, 
2010). The incidence of prostate cancer was fluctuated in the last decade showing 
unstable decrease until the year 2004, and then was stabilized until year 2008, but 
increases dramatically until 2011. Figure 1 shows the distribution of percentages of the 
reported cases of prostate cancer in Palestine between years 2000-2011. 
 
Figure1: Distribution of the reported Prostate Cancer between years 2000-2011   
(MOH reports 2000-2011) 
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The American cancer society, the Cancer research in the United Kingdom, and Mayo clinic 
showed similar models of risk factors for prostate cancer.  These risk factors are divided 
into two main categories: endogenous factors, and exogenous factors (Bostwick et al., 
2004). Endogenous factors such as family history of malignancy, especially prostate and 
breast cancers (Ghadirian et al., 1997,Hayes et al., 1995,Lesko et al., 1996a), race (Haas et 
al., 2008,Bostwick et al., 2004,Thompson et al., 2006), age (Haas et al., 2008,Bostwick et 
al., 2004,Thompson et al., 2006), and hormones (Barba et al., 2009,Bostwick et al., 2004). 
Exogenous factors such as lifestyle factors including diet, smoking, and physical activity 
(Tyagi et al., 2010,Severson et al., 1989,Kolonel et al., 2000,Kamel et al., 2006,Gann et al., 
1999,Cohen et al., 2000), environmental exposure to certain agents like endocrine 
disrupting chemicals (EDCs) and cadmium, and occupation especially in farming and 
rubber industry (Fritschi et al., 2007,Sass-Kortsak et al., 2007,Zeegers et al., 2004). Also 
diseases and health status were included in the models of risk factors for prostate cancer. 
Obesity (Fritschi et al., 2007,Gong et al., 2006,Putnam et al., 2000) and diabetes 
(Giovannucci et al., 1998,Gong et al., 2006,Kasper et al., 2009,Rodriguez et al., 2005). 
Other factors that may influence the occurrence of prostate cancer include: energy intake, 
marital status, anthropometry, sexual activity, and vasectomy (Hosseini et al., 
2010,Rodriguez et al., 2007,Park et al., 2007,Holt et al., 2008).  
Till to date, no study in Palestine investigated the risk factors for developing prostate 
cancer among men.  
Services presented to prostate cancer patients such as treatment and follow up are mainly 
offered in the cancer care centers distributed along the West Bank. BJGH in the central 
and the southern districts, and Al Watani Governmental Hospital in the northern districts 
are the two MOH governed cancer care centers. On the other hand Augusta Victoria 
Hospital in Jerusalem is a private referral hospital where limited services are presented to 
the prostate cancer patients. Treatment services including surgery, chemotherapy, and 
hormone therapy are delivered in the MOH governed cancer care centers. Since the 
radiation therapy is not available in the MOH governed cancer care centers, the prostate 
cancer patients who need such a treatment are referred to Augusta Victoria Hospital. 
Prostate cancer patients follow up are presented in the oncology clinics of the MOH 
governed cancer care centers. In some limited cases the patient may be referred to 
neighboring countries to get the needed services.         
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However, there is no active screening or preventive program dealing with prostate cancer 
in the Palestinian community. Hence, any research that focuses on the issue of prostate 
cancer determinants would be of great value to help start establishing national programs 
dealing with the risk and protective factors of prostate cancer. This study is a baseline 
study for decision makers to help in planning for a national strategy that can help in 
preventing this cancer and/or its complications. 
1.4 Aim of the study 
To identify the determinants of prostate cancer in the south area of West Bank.  
1.5 Objectives 
 To determine the relationship between lifestyle factors and prostate cancer. 
 To relate the sociodemographic factors with prostate cancer. 
 To determine the association between family history of malignancy and prostate 
cancer. 
 To determine the association between health status and prostate cancer. 
1.6 Expected outcome 
The study of the determinants of prostate cancer would increase the knowledge about 
these determinants and reveals the specific risk and protective factors in the Palestinian 
community, as well as address the groups at risk. Thereafter, programs are made focusing 
directly on these at risk groups and working on the specific risk and protective factors in 
the large community.  
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1.7 Thesis chapters 
The thesis  consists of six chapters. Chapter one is the introductory chapter, it contains a 
background of the study, study justification and problem statement, aim and objectives.  
Chapter two includes the literature review of the international and local studies and 
research that were conducted concerning prostate cancer epidemiology and 
risk/protective factors. Chapter three includes the study theoretical and conceptual frame 
work. In chapter four the study setting, methods, tools, sampling methods, field work, 
design, statistical analysis and ethical considerations are included. In chapter five all 
study results are presented. Finally, in chapter six the study findings are discussed and 
compared to the reviewed literature, and also the study conclusion and recommendations 
are presented.  
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Chapter Two: Literature review 
2.1 Introduction 
In this chapter the epidemiology of prostate cancer and the literature related to prostate 
cancer epidemiology will be presented.  
2.2 Epidemiology of prostate cancer 
2.2.1 Prostate cancer epidemiology worldwide  
Prostate cancer is a disease of increasing significance worldwide. In many industrialized 
nations such as the United States, it is one of the most common cancers and among the 
leading causes of cancer deaths (Jemal et al., 2006). In developing countries it may be less 
common, however its incidence and mortality has been on the rise (Delongchamps et al., 
2007).  
The International Agency for Research on Cancer (IARC) represents the most up to date 
information on the incidence of prostate cancer around the world. The highest rates are 
from the United States with 124.8 per 100,000 where African American men have an 
incidence rate of 185.4 per 100,000 and White Americans have an incidence rate of 107.8 
per 100,000. China has some of the lowest incidence rates (1.7 per 100,000). Among 
European countries, the incidence in Austria (region of Tyrol) is the highest (100.1 per 
100,000) compared to those reported from the eastern region (66.4 per 100,000). Tyrol has 
an organized, very thoroughly conducted screening program for prostate cancer (Haas et 
al., 2008). 
The clinical incidence, mortality, and prevalence of prostate cancer varies among various 
geographical regions of the world. The approach to screening, early detection initiatives 
and availability of treatment modalities has a major impact on disease epidemiology (Haas 
et al., 2008). 
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2.2.2 Prostate cancer epidemiology in Arab world 
Cancer is already a major problem in the Arab community, and the changing in the 
lifestyle and aging will raise the burden of this disease otherwise corrective strategies are 
adopted including reliable screening and early detection methods.  
The age-standardized incidence rates were ranging from 3 per 100,000 in Egypt to 20 per 
100,000 in Palestine (Salim et al., 2009). An Egyptian case-control study pointed to 
sausages, butter and natural ghee as risk factors, while vegetables were protective (Kamel 
et al., 2006). 
Screening for prostate cancer is not regular in most Arab countries. However, in some 
public awareness campaigns the PSA test offered as a screening method. More efforts 
should be done to minimize the burden of prostate cancer in the Arab communities.   
  
2.2.3 Prostate cancer epidemiology in Palestine   
In Palestine, prostate cancer accounts for 5.3% of all cancer cases.  The age-standardized 
incident rate is 20 per 100,000 populations.  It has a mortality of 4.8% of all cancer in year 
2010 (PHIC, 2010). 
Screening for prostate cancer is not a common practice in the Palestinian health care 
system like other Arab countries although the incidence of prostate cancer among 
Palestinians is higher than most neighboring communities. 
2.3 Dietary factors and prostate cancer risk 
In table 2.1, we reviewed studies that were concerned with foods and dietary items that 
might be associated with prostate cancer among different populations worldwide.  
A case-control study in USA  revealed that legumes negatively associated with prostate 
cancer (Kolonel et al., 2000b). A prospective cohort study in Hawaii-USA showed that rice 
and tofu were both associated with decreased risk of prostate cancer (Severson et al., 
1989).   
Similar finding were shown in studies in less economically developed countries. In Egypt a 
case control study concluded that vegetables were protective factors from prostate cancer. 
When comparing the amount of vegetables consumed weekly, eating three or more 
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servings of vegetables per week had an inverse significant association with prostate cancer 
(OR= 0.59) compared to eating less than one serving per week.  Eating tomatoes and 
cruciferous vegetables (OR=0.41) were found to have the greatest effect among all 
vegetables (Kamel et al., 2006).   
Meat and fat was shown in several studies as risk foods for prostate cancer. In two case-
control studies  in India (Kamel et al., 2006) and Egypt (Kamel et al., 2006,Tyagi et al., 
2010), meat, fish, and fat appeared to be positively associated with prostate cancer risk. 
Similarly, in a prospective cohort study in USA  red and processed meat consumption 
found to be risk factors for prostate cancer (Kamel et al., 2006,Sinha et al., 2009). On the 
contrary, prospective cohort study in Europe  found no association between dietary fat and 
prostate cancer risk(Crowe et al., 2008a). Another randomized placebo-controlled trial in 
USA and Canada  no association of any nutrient or supplement with prostate cancer risk 
were found (Kristal et al., 2010).     
2.4 Tobacco smoking and prostate cancer risk 
Table 2.2 shows a summary of studies that investigated the association of smoking and 
prostate cancer. 
A case-control study in Iran showed a non-significant increased risk for prostate cancer by 
seven times among cases using pipe smoking compared to controls  (Hosseini et al., 2010). 
Another population-based case-control study conducted in Delhi, India  suggested that the 
odds ratio of current and past filter cigarette smoker had higher risk for development of 
prostate cancer but the association was statistically significant only in the case of past 
smokers (OR: 5.16, 95% CI: 2.13-12.51) (Tyagi et al., 2010).  
In a prospective cohort study in USA (Hsing et al., 1990) the authors concluded that 
tobacco  may be a risk factor for prostate cancer. As the relative risk for smokeless tobacco 
users in form of shewing was (RR=2.1 95% CI, 1.1-4.1), and the smoking relative risk 
(RR=1.8 95% CI, 1.1-2.9). While as, in two case-control studies in Egypt (Kamel et al., 
2006) and in USA (Yu et al., 1988) there were no differences in smoking habits between 
cases and controls.  
In the studies that dealt with the effect of smoking on survival of prostate cancer patient, a 
prospective mortality study in USA (Rodriguez et al., 1997) suggested that cigarette 
smoking was associated with fatal prostate cancer with a rate ratio (RR=1.34 95% CI, 
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1.16-1.56). Another prospective cohort study in USA (Hsing et al., 1990,Watters et al., 
2009)  reported an increased risk of fatal prostate cancer (hazard ratio=1.69, 95%CI: 1.25, 
2.27). That mean smoking may adversely affect survival in prostate cancer patient.                                      
2.5 Alcohol consumption and prostate cancer risk 
Table 2.3 shows a summary of studies that studied the effect of alcohol consumption on 
prostate cancer risk. 
A prospective cohort studies in USA (Kalish et al., 2000,Watters et al., 2010) revealed that 
the risk of non-advanced prostate cancer was 25% higher for men consuming six or more 
drinks daily (hazard ratio=1.25, 95% CI, 1.13, 1.37), 19% higher for men consuming three 
to six drinks daily, and 6% higher for men consuming up to three drinks daily, compared 
with nondrinkers. This study found no association between alcohol consumption and 
advanced prostate cancer, but an inverse association with fatal prostate cancer was found. 
 Another Prospective cohort study in USA reported that moderate liquor consumption was 
associated with a significant 61-97% increased risk of prostate cancer(Sesso et al., 2001). 
While as, beer and wine were not associated with prostate cancer risk. And a case-control 
study conducted in Canada (Sharpe and Siemiatycki, 2001) reported that the risk of 
prostate cancer increased with increasing cumulative  consumption of alcoholic beverages 
(beer, wine, and spirits) adjusted odds ratio was (OR=1.8 95% CI, 1.2-2.7). Beer 
consumption showed the strongest association with increased prostate cancer risk adjusted 
odds ratio (OR=1.6 95% CI, 0.9-2.5).  
 In contrast, there were two case-control studies in USA (Schoonen et al., 2005,Yu et al., 
1988), and one prospective cohort study in Europe (Rohrmann et al., 2008) concluded that 
there was no association between alcohol consumption and risk of prostate cancer. 
Nevertheless, a case-control study in USA (Schoonen et al., 2005) suggested that the red 
wine consumption may be associated with reduced relative risk of prostate cancer Each 
additional glass of red wine consumed per week showed a statistically significant 6% 
decrease in relative risk (OR=0.94 95% CI, 0.90–0.98).  
2.6 Physical activity and prostate cancer risk 
Table 2.4 shows a summary of some studies that investigated the relation between physical 
activity and risk of prostate cancer. 
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A prospective cohort study in Norway (Nilsen et al., 2006) suggested that recreational 
physical activity was associated with reduced risk of advanced and fatal prostate cancer. 
The relative risk of those who reported high physical activity compared to those with no 
physical activity was (RR=0.64 95% CI, 0.43-0.95) for advanced prostate cancer, and 
(RR=0.67 95% CI, 0.43-0.95) for fatal prostate cancer.  
While as, a prospective cohort study conducted in the Netherland (Zeegers et al., 2005) 
showed no association between physical activity and risk of prostate cancer. Neither in 
non-occupational physical activity for more than 90 minutes daily versus less than 30 
minutes daily the rate ratio was (RR=1.01 95% CI, 0.81-1.25), nor for history of sport 
participation versus never participated (RR=1.04 95% CI, 0.90-1.22). And in another 
prospective cohort study in USA (Liu et al., 2000) the authors reported that the relative 
risks for prostate cancer associated with exercise vigorous enough to work up a sweat were 
1.0 (referent) for frequency less than once per week, 1.02 (95% CI : 0.82–1.26) for once 
per week, 1.07 (95% CI : 0.90–1.27) for 2–4 times per week, and 1.11 (95% CI : 0.90–
1.36) for 5+ times per week.     
In a prospective cohort study in USA ((Liu et al., 2000,Patel et al., 2005) findings 
suggested that the risk of overall prostate cancer between men who reported high physical 
activity and men who reported no physical activity was not different, the hazard rate ratio 
was (RR=0.90, 95% CI, 0.78-1.04). But the increased incidence among those who reported 
no physical activity was observed in aggressive prostate cancer (RR=0.69 95% CI, 0.52-
0.92). 
Similarly, in a case-control study in Sweden (Wiklund et al., 2008) which reported that 
comparing the most active with the least active men, total physical activity was not 
associated with either localized disease (OR = 0.95, 95% CI = 0.67–1.34) or advanced 
disease (OR = 1.19, 95% CI = 0.83–1.71). Another case-control study in Italy (Pierotti et 
al., 2005) revealed similar results as the odds ratio for prostate cancer for the highest level 
of physical activity men compared with the lowest level men was (0.94 95% CI, 0.75–
1.17).  In addition, a case-control study in Canada (Friedenreich et al., 2004) provided 
inconsistence evidence for the association between physical activity and prostate cancer 
risk. 
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2.7 Occupational factor and prostate cancer risk 
Table 2.5 summarizes some studies that investigated the correlation between occupation 
and risk of prostate cancer.  
a prospective study in Sweden (Dich and Wiklund, 1998) revealed that pesticides 
applicator are at increased risk of prostate cancer with incidence ratio (IR=1.13 95% CI, 
1.02-1.24). Likewise, a retrospective study (Sharma-Wagner et al., 2000) also in Sweden 
revealed the same result. In addition, this retrospective study (Sharma-Wagner et al., 2000) 
suggested that exposure to cadmium, herbicides, and fertilizers during the occupational 
activity increase the risk of prostate cancer.  
On the other hand, two case-control studies in Australia (Fritschi et al., 2007) and in 
Canada (Sass-Kortsak et al., 2007) did not provide strong evidences for significant 
occupational risk factors for prostate cancer.  Likewise, a prospective study in Netherland 
(Zeegers et al., 2004) found that the association between occupation and risk of prostate 
cancer can not be confirmed with confidence. (See table 2.5 for more details). 
2.8 Family History of prostate cancer and prostate cancer risk 
In table 2.6 shows the summary of studies that investigated the relation between family 
history of prostate cancer and the risk of prostate cancer. 
Two case-control studies one in Massachusetts, USA (Lesko et al., 1996a) and another in 
Maryland (Steinberg et al., 1990) reported that prostate cancer risk was two times more 
among those who had father or brother with prostate cancer, odds ratio was (OR=2.3 95% 
CI, 1.7-3.3) and relative risk was (RR=2 95% CI, 1.2-3.3) respectively. Moreover, the risk 
was increased when two or more relatives had a history of prostate cancer (OR=3.9 95% 
CI, 1.7-52). Another population based case-control study in Canada (Ghadirian et al., 
1997) revealed that 15% of the cases reported at least one relative with history of prostate 
cancer, compared with 5% of the controls, giving a relative risk (RR=3.3 95% CI, 2.18-
5.05). Likewise, in USA case-control study (Hayes et al., 1995) the odds ratio was 
(OR=3.2 95% CI, 2.0-5.0) among those with first degree relatives with history of prostate 
cancer.  
Similarly, two prospective cohort studies conducted in USA (Cerhan et al., 1999,Kalish et 
al., 2000) concluded that the family history of prostate cancer was a strong risk factor of 
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prostate cancer. Where the relative risk values of prostate cancer associated with family 
history were (RR=3.2 95% CI, 1.8-5.7) for both studies.  (See table 2.6 for more details).  
2.9 Obesity and prostate cancer risk  
Table 2.7 shows studies that aimed to find the relation between obesity and prostate cancer 
risk. 
A randomized placebo-controlled trial in the USA (Gong et al., 2006) suggested that 
obesity increase the risk of high grade prostate cancer (OR=1.29  95% CI, 1.01-1.67),  but 
decreases the risk of low grade prostate cancer (OR=0.82 95% CI, 0.69-0.98). Two 
retrospective studies in the USA (Putnam et al., 2000) and in Japan (Masuda et al., 2012) 
found that the obesity is a risk factor for more clinically significant prostate cancer.  
A prospective study conducted in USA (Rodriguez et al., 2007) reported that BMI was 
inversely associated with low grade prostate cancer risk (RR=0.84 95% CI, 0.66-1.06). But 
BMI was positively associated with high grade and fatal prostate cancer risk (RR=1.2 95% 
CI, 0.96-1.55) and (RR=1.54 15% CI, 1.06-2.23).  
A prospective study in USA (Hernandez et al., 2009) reported that men who gained more 
than 10 lb have an increased risk of advanced prostate cancer with relative risk (RR=2.12 
95% CI, 1.19-3.78). Likewise, another prospective cohort study in Europe (Pischon et al., 
2008) concluded that abdominal adiposity may increase the risk of advanced prostate 
cancer. (See table 2.7 for more details). 
Weak positive effects were observed for high body mass index on prostate cancer risk was 
the conclusion of a case-control study (Yu et al., 1988) conducted in USA. 
2.10 Diabetes and prostate cancer risk 
Table 2.8 shows the summary of studies that investigated the relation of diabetes and 
prostate cancer risk. 
In prospective cohort study in USA (Kasper et al., 2009) the authors concluded that the 
risk of prostate cancer was reduced among diabetic men comparing with non-diabetic men 
with a hazard ratio (HR=0.83 95% CI, 0.74-0.94). This study also concluded that the 
protective effect of diabetes is more obvious as the time since the diabetes diagnosis is 
longer, in men who diagnosed since 6-15 years ago the hazard ratio (HH=0.75 95% CI, 
0.61-0.93), and since more than 15 years ago (HH=0.78 95% CI, 0.63-0.96). Similar 
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results was revealed from another prospective cohort study in USA (Rodriguez et al., 
2005) where the risk of prostate cancer was reduced in men who diagnosed as diabetics 
since 4 years and more (Rate Ratio=0.67 95% CI, 0.60-0.75). But another prospective 
cohort study in USA (Giovannucci et al., 1998) reported that the significant reduction in 
risk of prostate cancer was among diabetic men who diagnosed as diabetic since more than 
10 years (RR=0.54 95% CI, 0.37-0.78).  
A randomized placebo-controlled study in USA (Gong et al., 2006) revealed that diabetes 
was associated with a 47% (OR=0.53 95% CI, 0.34-0.83) reduced risk of low-grade 
prostate cancer and a 28% (OR= 0.72 95%- CI, 0.55-0.94) reduced risk of high-grade 
prostate cancer. Likewise in another prospective cohort study in USA (Waters et al., 
2009b) where the risk of prostate cancer was reduced among diabetic men compared with 
non-diabetic ( RR=0.81 95% CI, 0.74-0.87).  (See table 2.8 for more details). 
2.11 Sexually transmitted diseases and prostate cancer risk 
Table 2.9 summarizes studies that deal with the relation between sexually transmitted 
diseases and prostate cancer risk. 
A case-control study in USA (Dennis et al., 2009) reported that herpes simplex virus-2 
(HSV2) was associated with increased risk of prostate cancer (OR=1.6 95% CI, 1.05-2.44), 
the association was increased more obviously if the HSV2 was diagnosed before 60 
months before prostate cancer diagnosis (OR=2.04 95% CI,  1.26-3.29). Another  two 
case-control studies one in USA (Huang et al., 2008) and one in Cuba (Fernandez et al., 
2005) both revealed an association of sexually transmitted disease and increased risk of 
prostate cancer in cases with one or more STDs (OR=1.3 95% CI, 1.0-1.6), (OR=1.7 95% 
CI, 1.1-2.5) respectively. A case-control study in USA (Sarma et al., 2006) concluded that 
the previous diagnosis of gonorrhea and prostatitis in black men increased the risk of 
prostate cancer (OR=1.78 95% CI, 1.13-2.79) and (OR=4.93 95% CI, 2.79-8.74) 
respectively.   
A meta analysis study (Taylor et al., 2005) reported that significant elevated odds ratios for 
prostate cancer were demonstrated for any STDs (1.48, 95% confidence interval [CI] 1.26–
1.73), gonorrhea (1.35, 95% CI 1.05–1.83), and human papillomavirus (1.39, 95% CI 
1.12–2.06). 
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On the other hand, a prospective cohort study in USA (Sutcliffe et al., 2006) concluded 
that there is no statistically significant association between gonorrhea and syphilis and risk 
of prostate cancer. Although, a positive association was observed between prostatitis and 
risk of prostate cancer in younger group of men aged less than 59. 
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Table 2.1: Studies on dietary factors and risk of prostate cancer. 
 
 
Authors Location and date Study design Sample 
size 
Conclusion 
(Kristal et al., 
2010) 
USA & Canada Randomized placebo-controlled 
trial 
9559 No associations of any nutrient or supplement with prostate cancer risk 
overall. 
(Tyagi et al., 2010) Delhi 1998-2000 Population based case-control  303:606 Cigarette smoking, alcohol consumption and dietary items like meat 
and fish to be considered as potential risk factors for PC. 
(Sinha et al., 2009) USA 1995-2003 Prospective  cohort study 175343 Red and processed meat positively associated with PC. 
(Crowe et al., 
2008b) 
Europe 2008 Prospective  cohort study 142520 No association between dietary fat and PC risk. 
(Kamel et al., 
2006) 
Egypt, 2004 Hospital based case-control study 
 
50:50 Fats in the form of butter/natural ghee, sausages might induce PC.  
Regular consumption of vegetables has a protective effect from PC. 
(Cohen et al., 
2000) 
Seattle, WA. Population based case-control study 628:602 High consumption of vegetables, particularly cruciferous vegetables, is 
associated with a reduced risk of prostate cancer. 
(Kolonel et al., 
2000a) 
USA & Canada Multicenter  case-control study 1619:161
8 
Legumes (not limited to soy products) and certain categories of 
vegetables may protect against PC. 
(Gann et al., 1999) USA 1982-1995 Nested Case-Control Study 578:1294 Increased consumption of tomato products, as part of a diet generally 
rich in fruits and vegetables, might reduce PC risk. 
(Severson et al., 
1989) 
Hawaii 1965-1986 Prospective cohort study 7999 Increased consumption of rice and tofu might decrease risk for PC 
Consumption of seaweeds was associated with an increased for PC No 
relationship with total fat and total protein. 
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Table 2.2: Studies on tobacco smoking and prostate cancer risk. 
 
Authors Location and date Study design Sample size Conclusion 
(Hosseini et al., 
2010) 
Iran 2005-2008 Population based case-control study 137:137 Potential risk factors for prostate cancer in 
exploratory analysis included family history of 
prostate cancer, history of other cancer, prostatitis, 
alcohol consumption, pipe or hookah smoking, 
walking to work, duration of occupational physical 
activity, intensity of occupational physical activity, 
body mass index, and older age. 
(Tyagi et al., 2010) Delhi 1998-2000 Population based case-control study 303:606 Past smoking and current alcohol consumption 
significantly increased the risk of prostate cancer. 
(Watters et al., 
2009) 
USA  2009 Prospective cohort study 283312 Current and former smokers may be at decreased 
risk of being diagnosed with prostate cancer, and 
current smokers are at an increased risk of dying 
from prostate cancer 
(Kamel et al., 2006)  Egypt, 2004 Hospital based case-control study 
 
50:50 The present study did not reveal any significant 
differences in smoking habits between cases and 
controls 
(Rodriguez et al., 
1997) 
USA 1982-1991 Prospective mortality study 450,279 Suggest that smoking may adversely affect survival 
in prostate cancer patients 
(Hsing et al., 1990) USA 1966-1986 Prospective cohort study 17,633 The findings add to limited evidence that tobacco 
may be a risk factor for prostate cancer 
(Yu et al., 1988) USA 1988 Case-control Study 1162:3124 Cigarette smoking and alcohol consumption were 
not related to the risk of prostate cancer. 
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Table 2.3: Studies on alcohol consumption and prostate cancer risk 
 
 
Authors Location and date Study design Sample size Conclusion 
(Watters et al., 2010) USA 1995-2005 Prospective cohort  study 294707 Higher consumption of alcohol modestly increases 
non-advanced prostate cancer risk. 
(Rohrmann et al., 
2008) 
Europe 1992-2000 Prospective cohort study 142607 No association between the consumption of alcohol 
and prostate cancer in this cohort of European men. 
(Schoonen et al., 
2005) 
USA  Case-control study 753:703 The consumption of beer or liquor is not associated 
with prostate cancer. There may be, however, a 
reduced relative risk associated with increasing level 
of red wine consumption. 
(Sharpe and 
Siemiatycki, 2001) 
Montreal Canada 
1979-1985 
Case-control study 399:476 The result was consistent with an increase in the risk 
of prostate cancer due to alcohol consumption. 
(Sesso et al., 2001) Harvard USA 1988-
1993 
Prospective cohort study 7612 The study found a positive association between 
moderate alcohol consumption and risk of prostate 
cancer. 
(Yu et al., 1988) USA 1988 Case-control study 1162:3124 Cigarette smoking and alcohol consumption were not 
related to the risk of prostate cancer. 
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Table 2.4: Studies on physical activity and prostate cancer risk. 
 
Authors Location and date Study design Sample size Conclusion 
(Wiklund et al., 2008) Sweden  2001-2003 Population based case-control study 1449:1118 These findings do not support the hypothesis that 
physical activity uniformly protects against prostate 
cancer development. 
(Nilsen et al., 2006) Norway 1984-2001 Prospective cohort study 29110 Recreational physical exercise is associated with 
reduced risk of advanced prostate cancer and prostate 
cancer death 
(Zeegers et al., 2005) Netherland 1986-
2005 
Prospective cohort study 58279 The results of this current study do not support the 
hypothesis that physical activity protects against 
prostate 
cancer in men 
(Pierotti et al., 2005) Italy 1991-2002 Case-control study 1294:1451 No significant association was found between 
leisure-time physical activity and prostate cancer 
risk. 
(Patel et al., 2005) USA 1997-2002 Prospective cohort study 72,174 No association between recreational physical activity 
and overall prostate cancer risk but suggest physical 
activity may be associated with reduced risk of 
aggressive prostate cancer 
(Friedenreich et al., 
2004) 
Alberta Canada 
1997-2000 
Case-control study 988:1063 This study provides inconsistent evidence for the 
association between physical activity and prostate 
cancer risk 
(Liu et al., 2000) USA Prospective Study 22071 This study do not support the hypothesis that 
increased physical activity reduces the risk of 
prostate cancer 
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Table 2.5: Studies on occupational factor and prostate cancer risk. 
 
 
 
Authors Location and date Study design Sample size Conclusion 
(Fritschi et al., 2007) Australia 2001-2002 Population-based case–control study 1066:1272 The association of prostate cancer with several 
occupational exposures, including metals, PAHs, 
oils, pesticides, fertilizers and wood were examined 
in this study. No evidence that any of these 
exposures were found strong occupational risk 
factors for prostate cancer. 
(Sass-Kortsak et al., 
2007) 
Ontario, Canada 1995-
1998 
Population-based case-control study 760:1632 This study does not provide strong evidence for 
significant occupational risk factors for prostate 
cancer. 
(Zeegers et al., 2004) The Netherlands 
1986-1993 
Prospective cohort study. 58,279 None of the previously investigated associations 
between occupation and prostate cancer risk could be 
confirmed with confidence in this prospective study. 
(Sharma-Wagner et 
al., 2000) 
Sweden Retrospective Cohort Study 36269 Our results suggest that farmers; certain occupations 
and industries with exposures to cadmium, 
herbicides, and fertilizers; and men with low 
occupational physical activity levels have elevated 
prostate cancer risks 
(Dich and Wiklund, 
1998) 
Sweden Prospective cohort study 20025 An increased risk among pesticide applicators was 
found. Pesticide applicators are more exposed to 
pesticides than farmers in general 
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Table 2.6: Studies on family history of prostate cancer and prostate cancer risk. 
 
 
 
 
Authors Location and date Study design Sample size Conclusion 
(Kalish et al., 2000) Massachusetts 1987-
1997 
Prospective cohort study 1149 An association was found between prostate cancer 
incidence and a family history of prostate cancer. 
(Cerhan et al., 1999) Iowa  1999 Prospective cohort study 1557 Family history of prostate cancer is a strong prostate 
cancer risk factor, and also family history of breast 
cancer may be a prostate cancer risk factor. 
(Ghadirian et al., 
1997) 
Canada  
1989 - 1993 
Population-based case-control study 640:639 This study provides further evidence of familial 
aggregation of prostate cancer. 
 
(Lesko et al., 1996b) Massachusetts 1992-
1994 
Population-based case-control study 563:703 Prostate cancer risk was increased among men who 
reported a history of this cancer in either their fathers 
or brothers. 
(Hayes et al., 1995) USA    1986-1989  Population-based case control study 981:1315 A genetic component to prostate cancer is suggested 
by the familial tendency to prostate cancer observed 
in our case-control study. 
(Steinberg et al., 
1990) 
USA 1982-1989 Case-control study 691:640 The male relatives of men with prostate cancer  are at 
increased risk for development of the disease 
22 
 
Table 2.7: Studies on obesity and prostate cancer risk. 
Authors Location and date Study design Sample size Conclusion 
(Masuda et al., 
2012) 
Japan  Retrospective cohort study 3966 Japanese men within the overweight body mass index 
range who have an elevated prostate-specific antigen 
level have a significant risk of harboring prostate cancer, 
especially high-grade disease 
(Hernandez et al., 
2009) 
USA 2009 Prospective cohort study 83879 Adiposity and changes in adiposity between younger and 
older adulthood influence the development of prostate 
cancer. 
(Pischon et al., 
2008) 
Europe 1992-2000 Prospective cohort study 129,502 Abdominal adiposity may be associated with an 
increased risk of advanced prostate cancer. This 
association may be stronger among individuals with 
lower BMI 
(Rodriguez et al., 
2007) 
USA 1982-2003 Prospective cohort study 69991 Obesity increases the risk of more aggressive prostate 
cancer and may decrease either the occurrence or the 
likelihood of diagnosis of less-aggressive tumors.Men 
who lose weight may reduce their risk of prostate cancer 
(Gong et al., 
2006) 
USA Randomized placebo 
controlled trial 
18880 Obesity increases the risk of high-grade but decreases 
the risk of low-grade prostate cancer. 
(Putnam et al., 
2000) 
Iowa USA 1989-
1995 
Retrospective cohort study 1572 Obesity is a risk factor for more clinically significant 
prostate cancer. 
(Yu et al., 1988) USA 1988 Case-control study 1162:3124 Weak positive effects of borderline statistical 
significance were observed for high body mass, low 
physical exercise on prostate cancer risk. 
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Table 2.8: Studies on Diabetes and prostate cancer risk. 
 
Authors Location and date Study Design Sample size Conclusion 
(Kasper et al., 2009) USA 1988-2004 Prospective cohort study 4511 Diabetes is associated with reduced prostate cancer  
risk. 
(Waters et al., 2009a) USA 1993-2005 Prospective cohort study 86303 Diabetes is a protective factor from prostate cancer 
across population.  
(Gong et al., 2006) USA Randomized placebo-controlled trial 18880  Diabetic men are at lower risk of prostate cancer. 
(Rodriguez et al., 
2005) 
USA1992-2001 Prospective cohort study 72670 Diabetes is associated with reduced risk of prostate 
cancer but only several years after diagnosis of 
diabetes. 
(Giovannucci et al., 
1998) 
USA 1986-1994 Prospective cohort study 1401 Diabetes is associated with reduced prostate cancer 
risk. 
24 
 
 
Table 2.9: Studies on sexually transmitted diseases and prostate cancer risk. 
 
Authors Location and date Study design Sample size Conclusion 
(Dennis et al., 2009) USA 1993-2003 Nested Case-control study 267:267  An association between prostate cancer and HSV-2 
infection in sera collected 7 years before diagnosis. 
(Huang et al., 2008) USA 1993-2001 Nested Case-control study 868:1283 No consistent association with specific STIs and a 
borderline association with any versus none. 
(Sarma et al., 2006) USA, Michigan 1996-
2001 
Case-control study 129:703 A history of gonorrhea infection and prostatitis 
increased the odds of prostate cancer. 
(Dennis et al., 
2009,Sutcliffe et al., 
2006) 
USA 1992-2002 Prospective cohort study 36033 Gonorrhea, Syphilis, and clinical prostatitis do not 
seem to be risk factors for prostate cancer.  
(Fernandez et al., 
2005) 
Cuba 2998-2000  Case-control study 273:254 The study supports the hypothesis that an infectious 
factor related to sexual behavior could be involved in 
the occurrence of prostate cancer. 
(Taylor et al., 2005)  Meta-analysis  Significant elevated ORs for prostate 
cancer were demonstrated for any STDs,  gonorrhea, 
and  human papillomavirus 
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Chapter Three: Conceptual Framework 
3.1 Introduction 
In This chapter the study major definitions, international prostate cancer models, and study 
conceptual framework will be presented.   
3.2 Prostate Cancer Definition 
Prostate cancer is a disease in which cells in the prostate gland become abnormal and start to 
grow uncontrollably, forming tumors (Carroll, 2001). Along with the testicles and the seminal 
vesicles, the prostate secretes the fluid that makes up semen. The prostate is about the size of 
a walnut and lies just behind the urinary bladder. A tumor in the prostate interferes with 
proper control of the bladder and normal sexual functioning. Often the first symptom of 
prostate cancer is difficulty in urinating. However, because a very common, non-cancerous 
condition of the prostate, benign prostatic hyperplasia (BPH) also causes the same problem, 
difficulty in urination is not necessarily due to cancer. 
Cancerous cells within the prostate itself are generally not deadly on their own. However, as 
the tumor grows, some of the cells break off and spread to other parts of the body through the 
lymph or the blood, a process known as metastasis. The most common sites for prostate 
cancer to metastasize are the seminal vesicles, the lymph nodes, the lungs, and various bones 
around the hips and the pelvic region. The effects of these new tumors are what can cause 
death (Beers, 2004). 
As of the early 2000s, prostate cancer is the most commonly diagnosed malignancy among 
adult males in Western countries. Although prostate cancer is often very slow growing, it can 
be aggressive, especially in younger men. Given its slow growing nature, many men with the 
disease die of other causes rather than from the cancer itself. 
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3.3 Prostate cancer determinants models 
The American cancer society, the Cancer research in the United Kingdom, and the Mayo 
clinic showed similar models of risk and protective factors for prostate cancer.  These 
determinants are divided into two main categories: endogenous factors, and exogenous factors 
(Bostwick et al., 2004).  
Endogenous factors such as family history of malignancy, race, hormones, and age.  
Exogenous factors such as lifestyle factors including diet, smoking, and physical activity, 
environmental exposure to certain agents like endocrine disrupting chemicals (EDCs) and 
cadmium, and occupation especially in farming and rubber industry. Also diseases and health 
status especially diabetes mellitus and obesity were included in the models of determinants for 
prostate cancer. Other factors that have been included in some models are: energy intake, 
marital status, anthropometry, sexual activity, and vasectomy (American cancer society, 
2012). 
 
Figure 3.1 illustrates the study conceptual model which built upon the above theoretical 
models for prostate cancer determinants and beholds: 
 
 Lifestyle factors include: smoking, diet, physical activity, alcohol consumption. 
 Socio-demographic factors include: age, occupation, marital status, and education. 
 Health status factors include: diabetes mellitus, obesity, history of other malignancy, 
and history of sexually transmitted diseases. 
 Family history of malignancy factors include: family history of prostate cancer, family 
history of breast cancer, and family history of other malignancy. 
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Figure 3.1: Study conceptual framework 
 
3.4 Prostate Cancer risk factors 
3.4.1 Age 
The strongest known risk factor for prostate cancer is age, with very low risk in men under 50 
years of age and increasing risk with increasing age. The older the man the higher the risk and 
this ties in the post-mortem results that showed an approximately 80% of men by age 80 were 
shown to have cancer cells in their prostate (Sakr et al., 1996).  
A widely accepted paradigm in cancer research holds that the development of cancers is rate 
limited by the occurrence of oncogenic mutations. In particular, the exponential rise in the 
incidence of most cancers with age is thought to reflect the time required for cells to 
accumulate the multiple oncogenic mutations needed to confer the cancer phenotype. 
In the United States, >70% of all cases of prostate cancer are diagnosed in men>65 years of 
age. It is relatively rare for prostate cancer to be diagnosed in men <50 years of age, but after 
this age, the incidence and mortality rates increase exponentially(Haas et al., 2008). The 
probability of developing prostate cancer increases from 0.005% among individuals aged<39 
years to 2.2% (1 in 45) for those aged 40 to 59 years and 13.7% (1 in 7) for those aged 60 to 
79 years. Overall, the lifetime risk of developing prostate cancer is 16.7% (1 in 6) (Crawford, 
2003). 
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3.4.2 Family history and ethnicity 
Individuals from the same family and ethnicity share part of their genetic makeup and some of 
their environmental exposures (e.g., diet, carcinogens, socioeconomic status, and lifestyle) 
during part of their lives. Except for a common variant found in 3 case-control series of 
European ancestry (Hayes et al., 1995), no other major susceptibility genes for prostate cancer 
have been consistently found across populations. 
Many cancers begin when one or more genes in a cell are mutated, creating an abnormal 
protein or no protein at all. The information provided by an abnormal protein is different from 
that of a normal protein, which can cause cells to multiply uncontrollably and become 
cancerous. 
A person may either be born with a genetic mutation in all of their cells (germline mutation) 
or acquire a genetic mutation in a single cell during his or her lifetime. An acquired mutation 
is passed on to all cells that develop from that single cell (called a somatic mutation). Most 
prostate cancers (about 75%) are considered sporadic, meaning that the damage to the genes 
occurs by chance after a person is born. Prostate cancer that runs in a family, called familial 
prostate cancer, is less common (about 20%) and occurs because of a combination of shared 
genes and shared environmental or lifestyle factors. Hereditary (inherited) prostate cancer is 
rare (about 5%) and occurs when gene mutations are passed within a family from one 
generation to the next 
A family history of prostate cancer is one of the strongest known risk factors for this disease. 
It has been estimated that 5-10% of all prostate cancer cases and 30-40% of early-onset cases 
(men diagnosed <55 years) are caused by inherited susceptibility genes (Bratt, 2002). 
Risk increases two to three times for men with a first-degree relative diagnosed with prostate 
cancer. If the relative is <60 years old at diagnosis or more than one relative is affected (at 
any age), the individual’s risk is four times the average. These factors combine so that if more 
than one relative is affected by early-onset prostate cancer, the risk is increased by seven-fold 
(Johns and Houlston, 2003). 
A strong family history of breast cancer may also affect a man’s risk of prostate cancer, 
particularly if the family members were diagnosed under the age of 60. In particular, germline 
mutations in the breast cancer susceptibility gene, BRCA2, can predispose men to prostate 
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cancer, increasing the risk of developing prostate cancer up to five times in men overall, and 
more than seven times in men aged under 65 (Hemminki and Chen, 2005).  
3.4.3 Diet 
Fat is the dietary component most frequently associated with PC risk. The fatty acids in 
dietary fats can be divided into essential and non-essential fatty acids. The essential fatty acids 
are all unsaturated and derived directly from diet. These essential fatty acids can be divided 
into omega-6 and omega-3 fatty acids(Meyer and Gillatt, 2002).  
At a cellular level the essential fatty acids thought to influence cellular proliferation, the 
immune system and the potential of tumor to invade locally and metastasize(Rose and 
Connolly, 1991).They are also reported to affect prostoglandin synthesis and sex hormone 
levels; Androgenic stimulation may be a causative factor in the development of prostate 
cancer. Testosterone is converted to its active form DHT by 5α-reductase, DHT is necessary 
for the continuing growth and development of PC(Meyer and Gillatt, 2002). Different fatty 
acids have been shown to have beneficial and detrimental effects on the growth of prostate 
cancer cells. For example omega-6 fatty acid stimulates the growth of an androgen-
unresponsive PC line, whilist the omega-3 fatty acid inhibits the growth of this PC cell 
line(Rose and Connolly, 1992,Pandalai et al., 1996).  
The association between vitamin D deficiency and PC was initially noted in a study which 
showed a correlation between exposure to sunlight and rates of prostate cancer 
death(Schwartz and Hulka, 1990). Calcitriol; the biologically active compound of vitamin D 
significantly inhibits PC cell lines(Skowronski et al., 1993). 
3.4.4 Alcohol 
The mechanisms by which alcohol consumption exerts its carcinogenic effect have not been 
defined fully, although plausible events include: a genotoxic effect of acetaldehyde, the main 
metabolite of ethanol; increased estrogen concentration, which is important for prostate 
carcinogenesis; a role as solvent for tobacco carcinogens; production of reactive oxygen 
species and nitrogen species; and changes in folate metabolism (Boffetta and Hashibe, 2006).  
3.4.5 Smoking 
A higher risk of fatal prostate cancer in smokers compared to non-smokers has been shown in 
some studies (Rohrmann et al., 2007,Gong et al., 2008). However, no clear trends were shown 
with number of cigarettes smoked per day or between current, ex- and never-smokers. Two 
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large studies concluded that smoking is not likely to be linked to either the incidence or 
mortality of prostate cancer (Doll et al., 2005). 
3.4.6 Bodyweight 
Obesity is a major health problem worldwide and has been linked to several major cancers. 
However, it is not yet proven to be an important risk factor for prostate cancer. 
A recent meta-analysis reported a small borderline significant increase in prostate cancer risk 
with increasing body mass index (BMI). Some cohort studies indicate that obese men are at 
greater risk of dying from prostate cancer while others have reported a reduced risk of 
localized prostate cancer in men with a high BMI. Although the evidence is far from clear for 
prostate cancer, general health advice would be for men to maintain a healthy BMI. 
3.4.7 Medications 
Aspirin use appears to slightly reduce the risk of prostate cancer, several meta-analyses and 
large studies show. NSAIDs in general (including aspirin) may have a small protective effect, 
but overall the evidence is not clear. Ibuprofen does not appear to have a protective effect. 
Because of the potential adverse consequences of high intake of aspirin, such as 
gastrointestinal hemorrhage, it would not be recommended as a prophylactic measure. 
In the laboratory, cholesterol-reducing statins have shown possible chemopreventive 
properties against cancers. However, a systematic review of observational studies and 
randomized controlled trials found that statin-use was not associated with short-term cancer 
risk but an association with reduced longer-term risk cannot yet be ruled out. Further research 
on the effects of statin-use on prostate cancer risk or the course of the disease is needed. 
3.4.8 Sexually transmissible diseases 
Sexually-transmitted diseases and prostatitis may increase the risk of prostate cancer with a 
2005 meta-analysis reporting a 40% increased risk of prostate cancer in men with a history of 
gonorrhea or human papilloma virus infection. 
3.4.9 Endogenous hormones 
It has long been suggested that high circulating levels of sex hormones are associated with an 
increased risk of prostate cancer as most prostate cancers respond favorably to androgen-
deprivation and castrated men do not develop prostate cancer. However, the most recent 
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worldwide re-analysis of 18 prospective studies, including the EPIC study, has shown no 
association between endogenous sex hormones and risk of prostate cancer overall. 
Insulin-like growth factor (IGF-1) is an easily measurable protein that is involved in normal 
cell proliferation and death. Both a recent meta-analysis and a large Swedish study found that 
higher concentrations of IGF-1 were associated with an increased risk of prostate cancer with 
a clear dose-response relationship, as did a large case-control study. 
However, other studies including EPIC have shown no association. IGF-1 levels may mediate 
the effects of many environmental exposures as its levels are regulated by other cancer risk 
factors such as bodyweight, diet and physical exercise. The relationship between several 
components of the IGF system and prostate cancer is undergoing further investigation. 
3.5 Prostate Cancer Protective Factors 
3.5.1 Tomatoes 
Epidemiologic and case-control studies suggest that intake of tomatoes and tomato products is 
associated with a lower risk of prostate cancer (Giovannucci et al., 2002). It has been 
suggested that lycopene, a compound in raw and processed tomato products, may be 
responsible for the lower risk, although other carotenoids and phytochemicals in these 
products may also contribute to the benefit(Crawford, 2003). In a study of 2481 men, high 
levels of lycopene consumption were associated with a 16% lower risk of prostate cancer as 
compared with consumption of small amounts of lycopene (Giovannucci et al., 2002). A 
controlled dietary intervention study is needed to confirm the benefit of lycopene and tomato 
products. In addition, the mechanism by which lycopene may reduce risk remains to be 
established(Crawford, 2003). 
3.5.2 Selenium  
Several studies suggest that selenium, an essential trace element found largely in grains, fish, 
and meat, may also protect against prostate cancer(Vogt et al., 2003). In a population-based, 
case-controlled study of white and African American men, serum selenium was inversely 
associated with prostate cancer risk(Vogt et al., 2003). Men with the highest quartile of serum 
selenium had 29% lower risk than those in the lowest quartile. This pattern was similar for 
both whites and African Americans. The strongest relation was found for men with low serum 
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-tocopherol concentrations, suggesting that the benefit may relate to an antioxidant 
mechanism(Crawford, 2003). 
3.5.3 Diabetes Mellitus 
Men with diabetes mellitus appear to have a lower risk of developing prostate cancer. In a 
population-based cohort study conducted in Sweden, men hospitalized for diabetes had a 9% 
lower risk of prostate cancer, and those hospitalized for a diabetic complication had an 18% 
lower risk than men in other population-based registers (Weiderpass et al., 2002).  In a 
hospital-based, case-control study, diabetes was associated with a 40% lower risk of prostate 
cancer overall and a 53% lower risk of regional or advanced prostate cancer (Rosenberg et al., 
2002). This effect was found mainly in whites and Hispanics, but not in African Americans. 
Obesity and hyperinsulinemia are associated with diabetes, and both may reduce IGF-1 levels 
and alter endogenous steroid metabolism (Crawford, 2003).  
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Chapter four: Methodology 
4.1 Introduction 
In this chapter, study setting, study sample frame, study design, sampling, selection of the 
study population with its inclusion and exclusion criteria, study tools (questionnaire and blood 
analysis), field work and data collection, study statistical analysis method, as well as study 
ethical considerations are presented.  
4.2 Study setting 
BJGH is a central hospital in the southern part of the West Bank. It has many vital medical 
specialties such as orthopedic, cardiovascular, ENT, surgery and oncology departments. Each 
medical specialty has an in-patient ward and out-patient clinic. All patients’ records are kept 
in the paper filling archives presented within the hospital.  
The oncology department provides primary, secondary, and tertiary health care for cancer 
patients in the south of the West Bank. Diagnostic and therapeutic procedures are also 
presented at BJGH. These procedures include medical imaging and laboratory testing for 
diagnosis and follow-up, surgery and chemotherapy for curative and palliative entities. 
Patients could be admitted to the oncology ward to be under observation. Also cancer patients 
are followed up in the outpatient clinics by medical oncologists.  
4.3  Study Design 
This is a retrospective case-control study. The participants of this study are patients attending 
Biet Jala Governmental Hospital (BJGH).  The ratio of study cases to control group was 1:1.  
4.4 Study population 
Study cases were patients attending BJGH oncology clinic and/or admitted in the oncology 
ward and diagnosed as having prostate cancer of any grade during the time of the study data 
collection period, i.e. February 2013to May 2013.     
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Study control group were patients attending BJGH clinics except oncology and urology 
clinics, and/or admitted in any ward except oncology or urology wards during the time of data 
collection for this study. Control group had the same ages of the study cases. 
4.4.1 Study cases inclusion and exclusion criteria 
 Inclusion criteria: 
 Any male patient diagnosed with prostate cancer and the diagnosis is documented in 
his medical record. 
 Visiting the oncology out-patient clinic and/or admitted in the oncology ward as a case 
of prostate cancer. 
 Participants’ consent to participate in the study was required. 
 Exclusion criteria 
 Any male patient diagnosed as prostate cancer case but this diagnosis is not presented 
in the hospital archive. 
 Any male patient diagnosed as prostate cancer case but refused to sign the study 
consent form.  
4.4.2 Control group inclusion and exclusion criteria 
 Inclusion criteria 
 Any male patient attending BJGH for receiving health care. 
 Any male patient reported not to have prostate cancer or any type of malignancy and 
this approved by his medical record and PSA test. 
 Participants’ consent for the participation in the study was required too. 
  Exclusion criteria 
 Any patient reported to have any recent or previous diagnosis of any type of cancer. 
 Any patient visiting the urology clinic or admitted in the urology ward. 
 Any patient had an elevated PSA score testing. 
 Any male patient complies with the inclusion criteria but does not accept to participate 
in the study by signed consent. 
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4.5  Study period 
The study was carried out in February 2013 to May 2013. The questionnaire, the consent 
form, Ministry of Health approval and permission, and the logistic preparation were ready by 
the end of January 2013. Data collection and study population interviews started in February. 
After four months, the number of eligible participants that were included in the study was 60 
cancer cases and 60 controls.     
4.6  Sampling and sample size 
Before the study implementation, when reviewing patients files of the year 2012 about 70 
prostate cancer cases were seen in the oncology department. Those patients have to attend the 
clinics for follow up and chemotherapy sessions at least once monthly. Therefore, we 
expected to see at least 80% of these prostate cancer cases during the study period. Therefore, 
all prostate cancer patients attended BJGH during the study period were included in the study 
sample. Total number of study cases was 60 participants. 
4.7 Data source and study tools  
4.7.1 Participant’s medical record 
After selecting the study case participant, his medical record was explored to ascertain the 
prostate cancer diagnosis, date of diagnosis, and the PSA test score at the time of the 
diagnosis.    
4.7.2 Structured interview questionnaire 
A face-to-face interview questionnaire was developed using several previously validated 
questionnaires. The questionnaire was divided into sections to cover the study objectives.  
The full questionnaire, in Arabic is presented in Annex 1.  The following sections cover the 
questionnaire and source of questionnaire parts. 
 The socio-demographic section included questions about participant’s age, date of birth, 
marital status, age at marriage, number of siblings, profession, education, residence type, 
residence area, religion, and monthly income(University of Southern California 
Consortium, 2009). 
 The lifestyle section included questions about smoking habit, alcohol drinking, physical 
activity, diet, and complementary diet. We used the Harvard School of Public Health food 
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frequency questionnaires (FFQ) with some modifications such as adding some items and 
removing other items that irrelevant to our study objectives (Harvard School of Public 
Health, 2013). For the smoking and alcohol consumption we used Steps Arabic 
questionnaire of the WHO (WHO, 2013). 
 The health status part contains questions about the participant’s chronic diseases including 
history of diabetes mellitus type I and type II, hypertension, cardiovascular diseases, 
prostatic disorders, sexually transmissible diseases, and vasectomy. Also the questionnaire 
asked about the usage of some medications that contains statin, or aspirin, in addition to 
anti-diabetic and anti-hypertension drugs (University of Southern California Consortium, 
2009). 
 The last part of the questionnaire contained questions regarding the history of malignancy 
and the family history of malignancy especially prostate cancer and breast cancer. 
 
Questionnaire validity, reliability and piloting:  
A- Validity 
The study questionnaire and its objectives were sent to three specialists in the field of 
oncology and public health to be evaluated. Their comments were considered in reviewing 
each study question.  
B- Reliability  
In order to check the reliability of the study questionnaire a Cronbach’s Alpha Coefficient test 
was done for the different sections of the questionnaire excluding the sociodemographic 
section. The results were as follows: lifestyle section: 62%, health status section: 68%, and 
history of malignancy: 55%.  
 C-Piloting  
10% of the expected study population (six cancer cases and six non-cancer patients) filled in 
the study questionnaire at the Augusta Victoria Hospital cancer care center. These 
questionnaires data were entered to the SPSS program and analyzed. Its results were not 
included in the study sample.  Results obtained helped us modifying some questions and 
modify the SPSS program.  
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 4.7.3 Prostate Specific Antigen (PSA) test 
We examined the blood serum of each participant in the control group for the score of 
prostate specific antigen to exclude the probability of undiagnosed prostate cancer. The blood 
samples were collected in the same day of the interview then sent to a certified medical 
laboratory to be analyzed.   
At the laboratory the blood samples were centrifuged for five minutes with 3500 round per 
minute. The instrument used for centrifuge is (Labofuge 400) manufactured by Heraeas 
Instruments. In regards to PSA level measurement, the laboratory used the (Elecsys 2010) 
manufactured by Roch/ HITACHI. The reagent used to measure the PSA level was Elecsys 
and cobas e analyzers ref: 04641655 manufactured by Roch Diagnostics. The quality control 
procedure used the PreciControl Universal level one and two, which were measured 
periodically.  
PSA scores were considered according to the kit manufacturer values, were they are subject 
age dependent. Table 4.1 shows the normal PSA limit in relation to age: 
 
Table 4.1 Prostate Specific Antigen Normal values  
Age (y) PSA Score (ng/ml) Result 
<40 <1.4 Normal 
40-49 
         <2.19 
Normal 
50-59 <3.1 Normal 
60-69 <4.1 Normal 
>69 <4.4 Normal 
 
4.8 Field work 
Both study cases and control group were interviewed during their waiting time for clinic visit 
in the out-patients clinics or during their stay in the ward if they were inpatients.  
Before filling the study questionnaire, study aim and objectives were clarified for the participants.  
After the participant accepts to participate, he signed the consent form (Annex 2).  
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Height and weight of each participant were measured using the scales found at the clinic of 
the hospital.  None of the patients we interviewed was an inpatient at the time of the study. 
Same interviewer was performing the interviews with the cases and the controls.   
As for the controls’ PSA tests, the blood samples were collected in the phlebotomy room in 
the same floor of outpatient clinic. A laboratory technician collected an amount of 3-5 ml of 
blood from the control participants who agree to participate in the study by signing the 
consent form specially designed for this study. The laboratory technician used an 18G winged 
scalp vain set, a disposable vaccutainer and a plain tube for each subject. The collected 
samples were stored in Ice Box and moved to a certified laboratory for analysis. The time 
between collecting the samples and reaching the lab did not exceed four hours. 
4.9 Statistical analysis 
IBM SPSS 20 was used to enter, clean and analyze the collected data.   
For descriptive analysis, frequencies were calculated for all study variables and were 
presented in tables and figures.   
To examine the binary associations, univariate analysis was done using the cross tabulation 
and the significance of Pearson and Fisher exact chi square-as needed- at P-value 0.1 was 
calculated. 
One sample T-test was used to analyze the differences between PSA test score between the 
control group and the study cases at P-value of significance 0.05.  
Multivariate analysis was done to adjust for several factors. After doing the univariate 
analysis, all the variables that showed significant differences between study cases and control 
group (p-value < 0.1) were introduced in the multivariate analysis. Logistic regression model 
was used.  The logistic regression was used to compare odds ratio with confidence interval of 
90%. p-value < 0.1 and 90% confidence interval were used due to small sample size.  
The following variables were introduced into the logistic regression model: age, marital 
status, age at marriage, number of children, monthly income, fruit consumption, cruciferous 
vegetables consumption, cocked tomato consumption, homemade cheese consumption, eggs 
consumption, red meat consumption, processed meat consumption, type 2 diabetes mellitus, 
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cardiovascular diseases, history of prostitis, antidiabetic medication intake, multivitamin 
intake, history of prostate cancer in father, and history of prostate cancer in brother.  
4.10 Ethical approval 
In order to lunch this study, we got the approval from Al Quds University-School of public 
health research committee and Al Quds University Graduate Studies committee. We also 
obtained the permission to conduct this study from the MOH.  Also all participants were 
informed about the study aim and objectives and signed a consent form before participating 
(Annex 2). 
4.11 Variables operational definitions 
Age variable: composed of three categories (40-59, 60-69, and ≥70 years). 
Marital status variable: composed of three categories (single, married and widow).  
Age at marriage variable: composed of three categories (15-20, 21-25, and >25).  
Number of children variable: composed of three categories (≤ 4, 5-8, and ≥9). 
Place of residence variable: is the place in which the participant lives (refuges camp, urban, 
and rural). 
Years of education variable: composed of four categories (illiterate, 1-6, 7-9, 10-12, and 
>12 years). 
Employment status variable: composed of two categories (working and not working). 
Career variable: composed of two main categories (office job and field job). Office job 
includes teacher, accountant, clerk, engineer, trader, nurse, and silversmith. Field job includes 
farmer, construction worker, driver, painter, and carpenter. 
Religion variable: composed of two categories (Muslim, and Christian).  
Participant’s monthly income: composed of two categories (≤3000 NIS and >3000 NIS). 
Tobacco smoking variable: composed of two categories (smoking, not smoking). 
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BMI variable: weight in kilogram divided by the height in meter square, and composed of four 
categories (underweight: < 18.5, normal: 18.5-24.9, overweight: ≥25-29.9, and Obese: ≥ 30). 
Physical activity level variable: composed of three categories (high, medium, low). 
Food groups variable: composed of seven categories (fruits, vegetables, milk and milk 
products, animal products, beverages, and water). 
Frequency of food intake: composed of three categories (< two times weekly, 2-4 times 
weekly, and > four times weekly). 
Nutritional supplements intake variable: composed of (multivitamins, vitamin A, vitamin 
C, vitamin B complex, vitamin B6, vitamin E, vitamin D, Potassium, Calcium, Selenium, 
Zink, and folic acid). 
Health status variable: composed of (diabetes mellitus, cardiovascular diseases, 
hypertension, prostitis, sexually transmitted infections, prostate cancer, and any other 
malignancy). 
Medication used variable: composed of (Aspirin, anti-diabetic, anti-hypertension, and anti-
hyperlipidimic). 
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Chapter Five: The Results 
5.1 Introduction 
In this chapter, study results will be presented. Study population characteristics will be shown 
in a descriptive analysis. Univariate and multivariate analysis will also be presented in this 
chapter. 
5.2 Sociodemographic Variables 
Table 5.1 shows that 77% of the study population was older than 60 years of age. Of them, 
80% were married and their age of marriage was between 21-25 years old, and 53% had 5 to 8 
children. Of the study population, 12% was illiterate, and 14% had completed higher 
education Also, 53.3% of study population lived in urban areas.   
Of the study population, while 54% were  unemployed, 45.8% of those working in the past 10 
years had office work and 78.3% had a monthly income less than or equal NIS 3000        
(table 5.1).  
Comparing study cases and control group, table 5.1 shows that there are statistically 
significant differences (P <0.1) in marital status, age at marriage, number of children, and 
monthly income.   
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Table 5.1  Association between study cases and control group by socio-
demographic factors 
 
Total 
N=120 
Study cases 
N=60 
Control group 
N=60 P Value 
n (%) n (%) n (%) 
Age (years) 
40-59 years 27 (22.5) 10 (16.7) 17 (28.3) 
0.243 60-69 years 36 (30) 21 (35.0) 15 (25.0) 
≥70 years 57 (47.5) 29 (48.3) 28 (46.7) 
Marital Status 
Married 96 (80) 44 (73.3) 52 (86.7) 
0.068 
Widow 24 (20) 16 (26.7) 8 (13.3) 
Age at 
Marriage  
(years) 
15-20 years 29 (24.1) 20 (33.3) 9 (15.0) 
0.060 21-25 years 52 (43.3) 22 (36.7) 30 (50.0) 
>25 years 39 (32.5) 18 (30.0) 21 (35.0) 
Number of 
Children  
(persons) 
≤4 27 (22.5) 12 (20.0) 15 (25.0) 
0.064 5-8 64 (53.3) 28 (46.7) 36 (60.0) 
≥9 29 (24.2) 20 (33.3) 9 (15.0) 
Years of 
Education 
Illiterate 15 (12.5) 8 (13.3) 7 (11.7) 
0.157 
1-6 years 39 (32.5) 19 (31.7) 20 (33.3) 
7-9 years 37 (30.8) 21 (35.0) 16 (26.7) 
10-12 years 12 (10) 2 (3.3) 10 (16.7) 
>12 years 17 (14.2) 10 (16.7) 7 (11.7) 
 Employment 
Status 
Yes 55 (45.8) 28 (46.7) 27 (45.0) 
0.855 
No 65 (54.2) 32 (53.3) 33 (55.0) 
 Career in the 
Last 20 Years 
 Office job* 39 (32.5) 20 (33.3) 19 (31.7) 
0.845 
 Field job**  81 (67.5) 40 (66.7) 41 (68.3) 
 Career in the 
Last 10 Years 
Office job* 55 (45.8) 28 (46.7) 27 (45) 
0.979 Field job** 43 (35.8) 21 (35) 22 (18.3) 
Not working 22 (18.3) 11 (18.3) 11 (36.7) 
 Place of 
Residency 
Urban 64 (53.3) 35 (58.3) 29 (48.3) 
0.272 
Rural 56 (46.7) 25 (41.7) 31 (51.7) 
 Residence 
Type 
Private House 85 (70.8) 45 (75.0) 40 (66.7) 
0.315 
Apartment 35 (29.2) 15 (25.0) 20 (33.3) 
 Religion 
Muslim 104 (86.7) 52 (86.7) 52 (86.7) 
1.000 
Christian 16 (13.3) 8 (13.3) 8 (13.3) 
 Monthly 
Income 
≤3000 shekels 94 (78.3) 41 (68.3) 53 (88.3) 
0.008 
>3000 shekels 26 (21.7) 19 (31.7) 7 (11.7) 
* Teacher, Accountant, clerk, engineer, trader, nurse, silversmith. 
**Farmer, construction worker, driver, painter, carpenter. 
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5.3 Food and nutritional variables 
 Table 5.2 shows that 62.5% of the study population eats fruits 2-4 times weekly and 69.2% 
eat vegetables for more than four times weekly. Also, 83% consumes cruciferous vegetables 
less than two times weekly.  
Comparing study cases and control group, table 5.2 reveals statistically significant differences 
(P<0.1) in some food intake, i.e. fruits, cruciferous vegetables, and cocked tomato. 
Table 5.2 Association between study cases and control group by fruit and 
vegetables consuming. 
 
Table 5.3 shows that 55.8% of the study population drinks milk less than two times weekly, 
while 43% of the study population consumes yogurt from 2-4 times weekly.  Also, 68.3% and 
88.3% of the study population consumes homemade cheese and homemade butter less than 
twice weekly, respectively.  
As for meat and animal products, 53% of the population study eats eggs 2-4 times weekly. In 
contrast, 50% of the study population consumes red meat less than two times weekly. 
Whereas, fish was eaten 1-3 times monthly in 53% of this study population. 
In addition, 63.3 of the study population drink coffee more than four times weekly, compared 
with 20% of them drink cola more than four times weekly. 
 Total 
N=120 
Study cases 
N=60 
Control group 
N=60 P-value 
n (%) n (%) n (%) 
Fruits  
 
<2 weekly 15 (12.5) 8 (13.3) 7 (11.7) 
0.082  2-4  weekly 75 (62.5) 32 (53.3) 43 (71.7) 
> 4  weekly 30 (25) 20 (33.3) 10 (16.7) 
Vegetables 
 
≤4  weekly 37 (30.8) 15 (25.0) 22 (36.7) 
0.166 
> 4  weekly 83 (69.2) 45 (75.0) 38 (63.3) 
Cruciferous 
vegetables 
<2  weekly 100 (83.3) 43 (71.7) 57 (95.0) 
0.001 
≥ 2  weekly 20 (16.7) 17 (28.3) 3 (5.0) 
Cocked tomato 
 
<2  weekly 84 (70) 35 (58.3) 49 (81.7) 
0.005 
≥2  weekly 36 (30) 25 (41.7) 11 (18.3) 
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Comparing study cases and control group, table 5.3 reveals statistically significant differences 
(P<0.1) in some food intake, i.e. home-made cheese, eggs, red meat, and processed meat.  
The distribution of all studied food and nutrition variables are shown in annex (3). 
Table 5.3 Association between study cases and control group by some food and 
drinks consuming. 
 
Total 
N=120 
Study cases 
N=60 
Control Group 
N=60 
P- Value 
 Milk 
 
<2  weekly 67 (55.8) 35 (58.3) 32 (53.3) 
0.727 2-4 weekly 17 (14.2) 9 (15.0) 8 (13.3) 
> 4 weekly 36 (30) 16 (26.7) 20 (33.3) 
 Yogurt 
 
<2 weekly 35 (29.2) 22 (36.7) 13 (21.7) 
0.167 2-4 weekly 52 (43.3) 22 (36.7) 30 (50.0) 
> 4 weekly 33 (27.5) 16 (26.7) 17 (28.3) 
Homemade 
cheese  
  
<2 weekly 82 (68.3) 34 (56.7) 48 (80.0) 
0.005 2-4 weekly 21 (17.5) 17 (28.3) 4 (6.7) 
> 4 weekly 17 (14.2) 9 (15.0) 8 (13.3) 
Homemade 
butter 
<2 weekly 106 (88.3) 51 (85.0) 55 (91.7) 
0.255 
≥2 weekly 14 (11.7) 9 (15.0) 5 (8.3) 
Eggs 
 
<2 weekly 33 (27.5) 12 (20.0) 21 (35.0) 
0.050 2-4 weekly 64 (53.3) 32 (53.3) 32 (53.3) 
> 4 weekly 23 (19.2) 16 (26.7) 7 (11.7) 
Red meat 
 
<2 weekly 60 (50) 24 (40.0) 36 (60.0) 
0.025 2-4 weekly 49 (40.8) 27 (45.0) 22 (36.7) 
> 4 weekly 11 (9.2) 9 (15.0) 2 (3.3) 
Processed meat 
 
<2 weekly 93 (77.5) 41 (68.3) 52 (86.7) 
0.016 
≥2 weekly 27 (22.5) 19 (31.7) 8 (13.3) 
Fish 
 
<1 monthly 8 (6.7) 5 (8.3) 3 (5.0) 
0.325 1-3 monthly 64 (53.3) 28 (46.7) 36 (60.0) 
once weekly 48 (40) 27 (45.0) 21 (35.0) 
 Cola 
<2 weekly 62 (51.7) 32 (53.3) 30 (50.0) 
0.891 2-4 weekly 34 (28.3) 17 (28.3) 17 (28.3) 
> 4 weekly 24 (20) 11 (18.3) 13 (21.7) 
 Coffee 
<2 weekly 21 (17.5) 10 (16.7) 11 (18.3) 
0.931 2-4 weekly 23 (19.2) 11 (18.3) 12 (20.0) 
> 4 weekly 76 (63.3) 39 (65.0) 37 (61.7) 
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5.4 Lifestyle variables 
Table 5.4 demonstrates the association between study cases and control group by their 
lifestyle variables.  The table shows that 45% of the study population was smoker and 10% 
drink alcohol regularly. Moreover, 43.3% of the study population lived with high physical 
activity and 25.8 with low physical activity. Only 8.3% of this study population practice sport.  
No statistically significant differences were seen between study cases and control group in 
their lifestyle factors (p>0.1). (See table 5.4). 
Table 5.4 Association between study cases and control group by lifestyle variables. 
 Total 
N=120 
Study cases 
N=60 
Control group 
N=60 P-value 
N (%) N (%) N (%) 
 Tobacco 
smoking  
Yes 54 (45) 30 (50.0) 24 (40.0) 
0.271 
No 66 (55) 30 (50.0) 36 (60.0) 
 Alcohol 
drinking  
Yes 12 (10) 7 (11.7) 5 (8.3) 
0.543 
No 108 (90) 53 (88.3) 55 (91.7) 
 Physical 
activity level 
High 52 (43.3) 26 (43.3) 26 (43.3) 
0.477 Moderate 37 (30.8) 16 (26.7) 21 (35.0) 
Low 31 (25.8) 18 (30.0) 13 (21.7) 
 Sport  
Yes 10 (8.3) 5 (8.3) 5 (8.3) 
0.628 
No 110 (91.7) 55 (91.7) 55 (91.7) 
 
5.5 Health status 
5.5.1 Detection, treatment, and complications of PC in the study cases 
Figure 5.1 shows the means of PC detection. Of study cases, 68% of PC cases were detected 
after having disease signs and symptoms. In contrast, 32% of PC cases were detected by 
chance or when investigated for other medical conditions. The data also present that none of 
the study cases have been detected during a systematic screening.  
Figure5.2 presents the treatment method of prostate cancer among study cases. Chemotherapy 
was done for 30% of study cases and radiation was the least method used. 
Figure 5.3 shows the distribution of complications after having PC. The back and pelvic pain 
was the most common complication which was found in 28% of the study cases.   
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Figure 5.1 Distribution of study cases by means of PC detection 
 
Figure 5.2: Distribution of study cases by treatment method 
 
Figure 5.3: Distribution of study cases by PC complication 
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5.5.2 Prostate Specific Antigen (PSA) testing  
The PSA results for control group were within the normal range of its level (<4.4). The mean 
and standard deviation was 1.51 ±1.1, ranging from 0.27 to 4.15.    
The PSA levels for the study cases at time of diagnosis were available in 75% of study cases’ 
files. The mean value and standard deviation was 37.9±38.3, ranging 5.5 to 150. Figure 5.4 
shows the distribution of PSA levels among study cases at diagnosis.  
Comparing study cases and control group mean levels, a statistically significant difference in 
PSA value (P=0.001) with mean difference 16.7, standard deviation 30.5, 95% CI (10.7-22.7). 
Figure 5.5 Boxplot distribution of PSA between study cases and control group.  
 
 
Figure 5.4: Distribution of PSA levels (ng/ml) among study cases               
        N/A:not available (missed data from medical records) 
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Figure 5.5: Boxplot distribution of PSA between study cases and control group 
5.5.3 Univarate analysis for health status 
Table 5.5 shows that 32.5% of the study population had diabetes type 2 ; 45.8% had 
hypertension, 25% had cardiovascular diseases, and 41.7% had prostatitis at least once in the 
past. 
Table 5.5 Association between study cases and control group by health status  
 
Total 
N=120 
Study cases 
N=60 
Control group 
N=60 P-value 
n (%) n (%) n (%) 
 Type 2 diabetes 
Yes 39 (32.5) 15 (25.0) 24 (40.0) 
0.079 
No 81 (67.5) 45 (75.0) 36 (60.0) 
Hypertension 
Yes 55 (45.8) 30 (50.0) 25 (41.7) 
0.360 
No 65 (54.2) 30 (50.0) 35 (58.3) 
Cardiovascular diseases 
Yes 30 (25) 10 (16.7) 20 (33.3) 
0.035 
No 90 (75) 50 (83.3) 40 (66.7) 
Prostatitis 
Yes 50 (41.7) 35 (58.3) 15 (25.0) 0.001 
No 70 (58.3) 25 (41.7) 45 (75.0)  
Other Malignancy 
Yes 11 (9.2) 11 (18.3) 0 (0.0) 
0.001 
No 109 (90.8) 49 (81.7) 60 (100.0) 
 
49 
 
Table 5.6 showed that high percent (65.8%) of study population uses aspirin on daily basis, in 
addition to other medications for their health problems such as diabetes (45.8%).  However, 
only 10% takes multivitamins. Of this population 47.5% was over-weight and 34.2% was 
obese.  
The data shows statistically significant differences between study cases and control group (P 
< 0.1) in having diabetes type 2, cardiovascular diseases, prostatitis, using anti diabetic 
medication, and multi-vitamins intake. 
 
Table 5.6 Association between study cases and control group by medication use. 
  
Total 
N=120 
Study  
cases 
N=60 
Control  
group 
N=60 
 
n (%) n (%) n (%) P-value 
Aspirin  
Yes 79 (65.8) 38 (63.3) 41 (68.3) 
0.546 
No 41 (34.2) 22 (36.7) 19 (31.7) 
Anti-diabetic  
Yes 39 (32.5) 15 (25.0) 24 (40.0) 
0.079 
No 81 (67.5) 45 (75.0) 36 (60.0) 
Anti-hypertensive  
Yes 55 (45.8) 30 (50.0) 25 (41.7) 
0.360 
No 65 (54.2) 30 (50.0) 35 (58.3) 
Anti-hyperlipidemic  
Yes 48 (40) 27 (45.0) 21 (35.0) 
0.264 
No 72 (60) 33 (55.0) 39 (65.0) 
Multi vitamins  
Yes 12 (10) 9 (15.0) 3 (5.0) 
0.068 
No 108 (90) 51 (85.0) 57 (95.0) 
 BMI 
Normal 
20-25 
22 (18.3) 
10 (16.9) 12 (20) 
0.874 Overweight 
26-30 
57 (47.5) 
30 (49.2) 27 (45) 
Obese >30 41 (34.2) 20 (33.9) 21 (35) 
 
5.6 Family History of malignancy 
Data in table 5.7 shows that 4.2% of the study population had fathers’ history of PC, and 
7.5% had brothers’ history of PC. 10% of the study population had sisters’ history of breast 
cancer, and 1.7% had history of mothers’ breast cancer. 
In the family history of malignancy, the data shows statistically significant differences between 
study cases and control group (P Value <0.1) in their family history of PC (Table 5.7). 
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Table 5.7 Association between study cases and control group by family history of 
malignancy. 
 Total 
N=120 
Case 
N=60 
Control 
N=60 P Value 
n (%) n (%)  (%) 
Father Has Prostate 
Ca 
Yes 5 (4.2) 5 (8.3) 0 (0.0) 
0.022 
No 115 (95.2) 55 (91.7) 60 (100.0) 
Father Has Other 
Malignancy 
Yes 2 (1.7) 0 (0.0) 2 (3.3) 
0.154 
No 118 (98.3) 60 (100.0) 58 (96.7) 
Brother Has Prostate 
Ca 
Yes 9 (7.5) 8 (13.3) 1 (1.7) 
0.015 
No 111 (92.5) 52 (86.7) 59 (98.3) 
Brother Has Other 
Malignancy 
Yes 9 (7.5) 6 (10.0) 3 (5.0) 
0.298 
No 111 (92.5) 54 (90.0) 57 (95.0) 
Mother Has Breast Ca 
Yes 2 (1.7) 0 (0.0) 2 (3.3) 
0.154 
No 118 (98.3) 60 (100.0) 58 (96.7) 
Mother Has Other 
Malignancy 
Yes 7 (5.8) 4 (6.7) 3 (5.0) 
0.697 
No 113 (94.2) 56 (93.3) 57 (95.0) 
Sister Has Breast Ca 
Yes 12 (10) 8 (13.3) 4 (6.7) 
0.224 
No 108 (90) 52 (86.7) 56 (93.3) 
Sister Has Other 
Malignancy 
Yes 6 (5) 3 (5.0) 3 (5.0) 
1.000 
No 114 (95) 57 (95.0) 57 (95.0) 
 
   Multivariate analysis 
Table 5.8 shows that being a widow was associated with increased risk (4 times) to develop 
PC compared to married men. Similarly, people with lower monthly income are associated 
with increased risk (8 times) to develop PC compared to people with higher income.  Also, 
those who are consuming  less amounts of cruciferous vegetables (6 times), homemade cheese 
(10 times), and processed meat (5 times) were at increased risk to develop PC compared to 
those consuming higher amounts However, diabetic persons (3 times) and those with 
cardiovascular diseases (7 times) were at increased risk to develop PC compared to those not 
having these diseases.  
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Table 5.8 Multivariate model analysis of the associated variables with prostate 
cancer *  
 Sig AOR** 90% CI*** 
Marital status 
Widow  1.00  
Married 0.03 0.225 0.073-0.697 
Monthly income 
≤3000 NIS  1.00  
>3000 NIS 0.001 0.118 0.042-0.332 
Cruciferous 
vegetables intake 
<2 weekly  1.00  
≥ 2 weekly 0.019 0.154 0.041-0.571 
Homemade cheese 
intake 
<2 weekly  1.00  
2-4 weekly 0.002 0.108 0.034-0.345 
> 4 weekly 0.972 1.08 0.265-4.009 
Processed meat 
intake 
<2 weekly  1.00  
≥2 weekly 0.011 0.192 0.066-0.557 
Diabetes 
Yes 0.033 3.132 1.29-7.57 
No  1.00  
Cardiovascular 
diseases 
Yes 0.004 7.38 2.33-23.31 
No  1.00  
*All variables that were significant (p<0.10) in univariate analysis were included in a 
multivariate model (P value 0.1): i.e. age group, marital status, age at marriage, number of 
children, monthly income, fruits intake, cruciferous vegetables intake, cocked tomato intake, 
homemade cheese intake, eggs intake, red meat intake, processed meat intake, type II diabetes 
mellitus, cardiovascular diseases, history of prostatitis, antidiabetic drugs usage, 
multivitamins intake, history of prostate cancer of brother, and history of prostate cancer of 
father. **Adjusted odds ratio. ***Confidence interval. 
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Chapter Six: Discussion 
6.1. Introduction 
In this chapter, study results are summarized and compared to other studies results 
worldwide. Also, the results are interpreted and discussed. In the final part of the chapter 
study conclusions and recommendations are presented  
6.2.  Summary of the results 
The univariat analysis of the study data showed significant differences between study cases 
and control group in marital status, age at marriage, number of children, and monthly 
income variables. Also the consumption of fruits, cruciferous vegetables, cocked tomato 
and home-made cheese eggs, red meat, and processed meat showed significant differences 
between study cases and control group.  
As for the univariate analysis of the health status and family history of malignance 
variables, type 2 diabetes mellitus, cardiovascular diseases, multi-vitamin intake, anti-
diabetic medication, father with prostate cancer, and brother with prostate cancer all 
showed significant differences between study cases and control group.   
On the other hand the multivariate analysis of the study data showed that married men are 
at lower risk by five folds to develop prostate cancer. Also the study revealed that lower 
the family monthly income increase the risk by nine folds to have prostate cancer.  More 
weekly consumption of cruciferous vegetables, homemade cheese, and processed meat 
showed to decrease the risk of prostate cancer among the study population by six, ten, and 
five folds, respectively. In addition, the risk of prostate cancer among diabetics was three 
times more than non-diabetics. Similarly, having cardiovascular diseases increased the risk 
of prostate cancer by seven folds.  
6.3 Socio-demographic variables and prostate cancer 
Marital status: In our study, marital status was found to be significantly associated with 
prostate cancer after adjustment. Being married was inversely associated with having 
prostate cancer compared to those widowed men by five folds. However, this result is 
inconsistent with results revealed by other studies that indicated no association between 
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marital status and prostate cancer risk (Tyagi et al. 2010; Severson et al. 1989; Newell et 
al. 1987). A prospective cohort study in Norway found that the risk among divorced or 
separated men to develop prostate cancer was 56% higher compared to married men (Lund 
Nilsen et al. 2000).  
The incidence of prostate cancer is increased with older ages. In our study about 87% of 
the widows were older than 70 years at the time of data collection, this may explain the 
appearance of marital status to be associated with prostate cancer occurrence.    
Monthly income: In our study, low family monthly income was found to significantly 
increase the risk for prostate cancer by ten folds. In a Norwegian cohort study they found 
that the higher the socioeconomic status the higher the risk of prostate cancer (Lund Nilsen 
et al. 2000). This could be explained by the greater medical attention among those who 
may have a self-paid insurance, where medical check-ups are made on a regular basis 
In our study we included participants from the main cancer governmental hospital and 
most of its visitors, if not all, are insured patients who have no choice for other hospitals 
except the private hospitals or hospitals outside the country.  We expect that these people 
cannot afford going to more expensive health facilities due to their low income.  Patients 
from higher economic either go to private clinics and hospitals or to other advanced 
facilities outside the country.  Moreover, asking people to report their income in a survey is 
not so accepted among interviewees, which leaves a space for justifying this finding by a 
reporting bias. 
6.4 Lifestyle variables and prostate cancer 
Cruciferous vegetables: Our study suggests that the consumption of cruciferous 
vegetables was adversely associated with the risk of prostate cancer. The participants who 
consumed cruciferous vegetables more than twice per week were at lower risk of 
developing prostate cancer by six folds compared to those consumed less. This result is 
supported by results from two case control studies that found  people who ate greater 
amounts of cruciferous vegetables had a lower risk of prostate cancer (Jain et al. 1999; 
Kolonel et al. 2000).  On the other hand, other cohort studies  have examined a wide range 
of daily cruciferous vegetable intakes and found little or no association with prostate 
cancer risk (Key et al. 2004; Giovannucci et al. 2003; Schuurman et al. 1998).  
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Cruciferous vegetables contain a group of substances known as glucosinolates. During 
digestion the glucosinolates in cruciferous vegetables are broken down to form biologically 
active compounds such as indoles, nitriles, thiocyanates, and isothiocyanates. Indole-3-
carbinol (an indole) and sulforaphane (an isothiocyanate) have been most frequently 
examined for their anticancer effects (Smiechowska et al. 2008). The action of these 
substances on the molecular level is believed to be the mechanism in which cruciferous 
vegetables could prevent prostate cancer development. 
Home-made cheese: Home-made cheese in this study also appeared to be significantly 
associated with the risk of prostate cancer. Men who regularly have 2-4 portions per week 
of home-made cheese is at lower risk of prostate cancer by ten folds  compared to those 
who eat less than two portions weekly. In the European Prospective Investigations into 
Cancer and Nutrition (EPIC) Heidelberg cohort (Nimptsch et al. 2008) found that the K2 
vitamin (menaquinones) is adversely associated with prostate cancer risk (RR 0.65, CI 
1.06-3.9). White cheese is a good source of vitamin K2, which has an antiangiogenic 
effect, and also kills cancer cells directly.  
On the other hand, some studies revealed that dietary intake might increase the risk of 
prostate cancer (Bairati et al. 1998; Giovannucci et al. 1993; Kamel et al. 2006). This can 
be attributed to the presence of fat and fat affects testosterone levels which have an 
important role in prostate cancer development. However, these studies focused on the 
cheese made from full fat cow milk, which contains double amount of fat that contained in 
the cheese made from goat milk. In fact, the popular homemade cheese in our community 
is made from the domestic goats that are mainly raised locally. Therefore, goat milk 
homemade cheese appeared to be inversely associated with prostate cancer risk.  
Processed meat: This study found that consumption of processed meat is adversely 
associated with prostate cancer risk. As the consumption of processed meat more than 
twice weekly decreases the risk of prostate cancer to 5 folds compared to less weekly 
consumption (OR=0.19, 90% CI 0.066-0.557). 
In the reviewed literature, there are inconstancies in the results regarding the association 
between processed meat and risk of prostate cancer.  
Koutros et al in Iowa and North Carolina found no association between meat type or 
specific cooking method and prostate cancer risk. However, they concluded that intake of 
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well or very well done total meat was associated with a 1.26-fold increased risk of incident 
prostate cancer (95% CI, 1.02-1.54) and a 1.97-fold increased risk of advanced disease 
(95% CI, 1.26-3.08)(Koutros et al. 2008). 
In Washington, Rohrmann et al concluded that processed meat consumption was 
statistically insignificant associated with higher risk and total prostate cancer when 
comparing eating of five or more servings with eating of one or less servings of processed 
meat weekly(HR = 2.24; 95% CI 0.90-5.59)(Rohrmann et al. 2007).  
On the other hand, the Cancer Prevention Study II Nutrition Cohort found that   high 
consumption of cooked processed meats may increase the risk of prostate cancer among 
black men in the United States. This increase in risk was mainly due to the risk associated 
with consumption of cooked processed meats (sausages, bacon, and hot dogs) (RR, 2.7; 
95% CI, 1.3-5.3)(Rodriguez et al. 2006). 
The discrepancies between these results may depend on the type of the processed meat 
tested in each study population. In our community the most abundant processed meat in the 
market is made from poultry meat. In Egypt for example a study founded that sausages was 
a directly associated with prostate cancer risk, but these sausages was made from cow 
meat(Kamel et al. 2006). 
Tobacco smoking: The univariate analysis of the smoking data collected from both study 
cases and control group shows that 50% of the cases were currently smokers where 40% of 
the controls were currently smokers, although the difference was not statistically 
significant (P-value 0.27). We merged the past smokers and smokers in the same category.  
Studies worldwide revealed inconsistent results when relating tobacco smoking with 
prostate cancer risk. A case-control study in Iran showed a non-significant increased risk 
for prostate cancer by seven times among cases using pipe smoking compared to 
controls(Hosseini et al. 2010). Another population-based case-control study conducted in 
Delhi, India suggested that the association was statistically significant with a 5-fold 
increase only in the case of past smokers (Tyagi et al. 2010). 
On the other hand,  in two case-control studies in Egypt (Kamel et al. 2006) and in USA 
(Yu et al. 1988) there were no differences in smoking habits between cases and controls.  
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Alcohol consumption: Our study data showed that 11.7% of the study cases were regular 
alcohol drinker compared to 8.3% of the control group. The association between alcohol 
consumption and prostate cancer risk still a controversial issue in the literature ranging 
from adversely association to no association and positively association. 
The relation between alcohol consumption and prostate cancer risk were always shown in 
the literature to depend on type, amount, and frequency of alcohol consumption.  In our 
study the number of alcohol drinkers was too small to show the differences between study 
cases and control group, also the type of alcohol used was not considered during data 
collection. This may explain the insignificant difference between study cases and control 
group when alcohol consumption was the studied variable.  
Schoonen et al suggested that red wine consumption may be associated with a reduced 
relative risk of prostate cancer.  Each additional glass of red wine consumed per week was 
shown to decrease the risk by 6% (relative risk 0.94, 95% CI, 0.90–0.98)(Schoonen et al. 
2005). 
In contrast, two case-control studies in USA (Schoonen et al. 2005; Yu et al. 1988)  and 
one prospective cohort study in Europe (Rohrmann et al. 2008) concluded that there was 
no association between alcohol consumption and risk of prostate cancer. 
Moreover, a prospective cohort study in USA reported that moderate liquor consumption 
was associated with a significant 61-97% increased risk of prostate cancer(Sesso et al. 
2001).  
6.5 Health status variables and prostate cancer 
Type 2 diabetes mellitus: Type 2 diabetes mellitus found in our study to be positively 
associated with prostate cancer risk (OR=3.1, 90% CI 1.29-7.57). Our result contradicts the 
result from a meta-analysis that provided strong evidence that people with diabetes have a 
significant decrease in risk of developing prostate cancer (Bonovas et al. 2004). 
The Health Professionals Follow-Up Study confirmed by their study results the hypothesis 
that diabetes is associated with reduced prostate cancer risk (Kasper et al. 2009).  
A number of theories exist to explain this protective phenomenon, but the most prevalent 
mechanism that diabetes mellitus may lower prostate cancer risk through a reduction of 
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essential serum growth factors – insulin, insulin like growth factor (IGF-1), and 
testosterone (Kasper et al. 2008). But also, the type of diabetes medications the patient use.  
 Metaformin was shown in literature to decrease the risk for prostate cancer (Decensi et al. 
2010). The descriptive data of this study should that diabetes medications decreased the 
risk for prostate cancer but the association was not significant.   
The effect of diabetes on prostate cancer risk depends on the time since diagnosis (Zhu et 
al. 2004). In our study the history of diabetes diagnosis was not traced with the 
participants, and this may affect our result in this aspect.  
Cardiovascular diseases: Cardiovascular diseases in our study appeared to be positively 
associated with prostate cancer. Participants who reported to have a cardiovascular disease 
are at seven folds risk to develop prostate cancer compared to participants with no 
cardiovascular diseases. Our result is consistent with the results of a  hospital based case 
control study in New York which concluded that patients with history of coronary heart 
disease are at 2-fold higher risk to develop prostate cancer (Neugut et al. 1998). 
In contrast, a nested case control study in the United States, found that the coronary heart 
disease is adversely associated with prostate cancer (OR=0.72, 95% CI 0.62-0.84)(Driver 
et al. 2010). 
In our study neither the specific type of the cardiovascular disease nor the history of 
diagnosis were investigated. This could affect the result, as most of the studies studied the 
relation of coronary heart disease and prostate cancer risk, which is not the scope of our 
study. 
Obesity: The univariate analysis of our data yielded that 33.9% of the study cases were 
obese (BMI >30), compared to 35% of the control group (P-value 0.874). The difference 
was not significant in our study although some studies concluded that the obesity is 
positively associated with high grad prostate cancer risk and negatively associated with 
low grad prostate cancer (Gong et al. 2006; Masuda et al. 2012; Putnam et al. 2000; 
Rodriguez et al. 2007). 
In our study, the clinical type of prostate cancer was not considered, and this may have 
diluted the result and set the obesity out of the association with prostate cancer risk. 
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6.6 Family history of malignancy and prostate cancer 
Our study showed that there is no association between prostate cancer risk and family 
history of prostate cancer or any other type of malignancy. Lisko et al found in a 
population based case control study in Massasusetch that family history of prostate cancer 
was significantly affect the risk of prostate cancer, as the presence of family history of 
prostate cancer increased the risk of this cancer (OR=2.3, 95% CI, 1.7-3.3)(Lesko et al. 
1996).  
Lesko et al in their case control study found that the relation between the risk of prostate 
cancer and family history of prostate cancer may depend on the age of the patient and the 
age at diagnosis. As the prostate cancer patient getting older the effect of family history 
getting lesser and converted to be adversely associated if the disease diagnosed after the 
age of 74 (OR=0.76 95% CI, 0.38-1.5)(Lesko et al. 1996).  
Lesko et al results may interpret our result as our study included 48.3% of the cases of age 
70 years and older. 
6.7 Limitations of the study 
The contradiction of this study with other studies may be attributed to the relatively small 
number of the studied population. Also some biases might affect the results like 
information bias, recall bias, and selection bias. The study was limited in terms of time and 
finance, which in role prohibited more investigation and tests. Data provided from the 
patient’s records was limited to oncological status of each patient and the lack of reporting 
of other medical conditions the patients have.  
Some limitations of this study derived from the nature of the retrospective case-control 
study. The participants were asked about their lifestyle long time ago, the participants are 
patients who are under the effect of some medication, in addition to the old age of most of 
the participants, all these factors result in recall bias. 
Also, the reporting bias may be presented in our study as the participants are patients trying 
either to deny the role of their lifestyle or to blame any other factors except themselves, so 
some participants answered some questions in a way to achieve their perception.  
Moreover, the data of family history of malignancy in the patient record (Cancer Registry 
Information Form) are missed in most of the cases; therefore we could not extract reliable 
59 
 
family history. To compensate the defect in participant’s medical record each participant 
was asked about his family history of prostate cancer and this might be exposed to recall 
bias or information bias. 
6.8 Conclusion 
This study is the first one in Palestine that investigated the possible association between 
different factors whether protective or risk and prostate cancer occurrence. A hospital 
based retrospective case control study design was used to answer the study question. 
Most results of this study were expected and comparable to other international studies 
results, while some others were unexpectedly contradicted the literature. Marital status, 
monthly income, cruciferous vegetables consumption, homemade cheese intake, 
processed meat consumption, cardiovascular diseases, and type 2 diabetes mellitus 
appeared to be associated with prostate cancer either positively or negatively. Tobacco 
smocking, family history of prostate cancer, sexually transmitted infections, and tomato 
consumption showed no association with prostate cancer risk. 
6.9 Recommendations 
Recommendations for people at risk of prostate cancer 
 Living in a healthy lifestyle that helps preventing the diabetes mellitus and 
cardiovascular diseases. 
 Increase the consumption of fruits and vegetables especially cruciferous 
vegetables, and homemade cheese. 
 Perform a screening for prostate cancer on a regular basis. 
   
Recommendations for policy makers and health care team: 
 Providing more attention for the men cancers especially prostate cancer. 
 Establishing national initiatives for the encouragement of early detection of 
prostate cancer. 
 Introducing screening methods for early detection of prostate cancer 
including rectal digital exam, PSA test, and biopsy. 
 Modifying the national cancer registry to include more details related to each 
cancer type.  
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 Considering the prostate cancer detection when dealing with over 50 years 
old men. 
 Giving more attention to the groups at risk of prostate cancer to enable the 
early detection. 
 Work more on the modifiable lifestyle factors which eventually affect the risk 
of prostate cancer. 
Recommendations for public health researchers: 
 Conducting more detailed researches with larger sample size and including 
more hospitals and health care facilities. 
 Considering the type of prostate cancer (histopathology) and the date of first 
diagnosis. 
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   مرض السكري النوع الاول 48Q
   ارتفاع ضغط الدم 58Q
   ايين القلبمرض شر 68Q
   خلل/ التهاب في البروستاتا 78Q
   أمراض الجهاز التناسلي  88Q
 حدد نوع المرض 98Q
   ورم غير سرطاني 09Q
 حدد مكان الورم 19Q
   ورم سرطاني في البروستات 29Q
   يرالبروستاتغ في  ورم سرطاني 39Q
   هل اجريت لك عملة قطع القنوات المنوية؟ 49Q
 لا -2 نعم -1  ؟اول الأدوية التاليةهل تتن 
   الأسبرين 59Q
   علاجات السكري 69Q
   علاج ضغط الدم المرتفع 79Q
   nitatS(علاج الدهنيات في الدم ( 89Q
 
هل أصيب أحد من افراد العائلة باحد انواع السرطانات 
 التالية؟
 لا أعلم  جدة/ لأم جد/ة  لأب خال/ة عم/ة أخ/ت أب/أم
         سرطان البروستاتب 99Q
         البروستات غيربسرطان  001Q
         بسرطان الثدي 101Q
         الثدي غيربسرطان  201Q
في حال عدم وجود الإصابة بسرطان البروستات هل تقوم بعمل فحوصات  301Q
 وقائية (مسحية) لسرطان البروستات؟
 لا -2 نعم -1
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 |_____| سم   الطول (سم) 401Q
 |_____| كغم  (كغم) قبل التشخيص كوزنكم كان  501Q
 |_____| كغم  كم وزنك حاليا 601Q
  
 خاص بمرضى سرطان البروستات
  عن طريق الصدفة -3 بواسطة إجراء مسح  وقائي -2 ظهور أعراض المرض -1 كيف تم اكتشاف اصابتك بسرطان البروستات؟ 701Q
  تات؟البروسكيف تم تشخيص الإصابة بسرطان  801Q
 
 أخذ عينة من البروستات -3 الموجات فوق الصوتية -2 الفحص السريري-1
ما هو نوع العلاج الذي خضعت له منذ اصابتك  901Q
 (بمرض سرطان البروستات؟ (متعدد الاجابات
 عملية جراحصية-3 العلاج الهرموني-2 العلاج الإشعاعي-1
  غير ذلك -0 العلاج الكيماوي-4
عاني من احدى هذه المضاعفات نتيجة هل ت 011Q
 للإصابة بسرطان البروستات؟
ضعف في الوظيفة  -1
 الجنسية
عدم القدرة على التحكم  -2
 بنزول البول
آلام في منطقة الحوض أو -3
 الظهر
   نزول دم مع البول-4
 
 
هل تود اضافة اية معلومه اخرى 
 _______________للاستمارة______________________________________
 ______________________________________________________________________
 النهاية
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 البروستاتا في فلسطين ة او لحدوث مرض سرطان غدةالعوامل المساعدة للوقاي
.  ومن مضاعفات الاصابة ض التي تزداد نسبة حدوثها مع تقدم العمرامرمن الايعد ، ولرجالا غدة البروستاتسرطان  يصيب       
 ه فهيحدوثالتي تسهم في سباب الأ اماخلل في الجهاز البولي، فقدان الوزن، كما قد يؤدي إلى الوفاة في حالة عدم علاجه بشكل مناسب. وبه 
الوقاية منه وتقلل من احتمالية الاصابة به مثل تناول الاسماك لى التي قد تساعد ععوامل ال العديد منغير معروفة بشكل كامل، ومع ذلك فهناك 
 .والفواكهة مع العلم ان عوامل اخرى قد تساعد على حدوثة مثل التدخين
في المجتمع الفلسطيني والعوامل  غدة البروستاتسرطان  العوامل المرتبطة بحدوث معرفة إلى بحثال هذا ومن هنا، يهدف        
باجراء مقابلات مع المرضى المصابين بهذا المرض والمراجعين لعيادات واقسام  الاخرى التي قد تساعد على الوقاية منه. لذلك سنقوم 
لهذه العيادات والغير مصابين به لمعرفة العوامل التي ساعدت على حدوثة عند وعينة اخرى من المراجعين  فى بيت جالا الحكوميمستش
ند المصابين وعدم حدوثة عند المجموعة غير المصابة، والتي قد تسهم في معرفة الاسباب التي قد تساعد في الوقاية منه والحد من مضاعفاته ع
 الاخرين. . 
 من آملينانة، الاستب أسئلة على الإجابة منكم نرجو لذاة، الدراس بأهداف خاصة ةأسئل على حتويت انةاستب بتجهيز قمنالقد        
 نبأ علما .سؤال كل قبل الواردة التعليمات حسب عليها الإجابة و بتمعن كل فقرة بقراءة و تامة بموضوعية الأسئلة كآفة إجابة حضرتكم
 نرجو لذاا. به ستدلون التي المعلومات في التامة السرية لكم فقط ونضمن العلمي البحث لأغراض ستستعمل انةالاستب في الواردة المعلومات
 .الدراسة هذه أهداف لإتمام المشاركة على بالموافقة التوقيع منكم
كما سنقوم بسحب عينة دم للاشخاص غير المصابين به لتحديد وضع غدة البروستاتا لديهم والتي يستطيعون الحصول على        
 قوا على المشاركة في البحث.تنيجتها ان واف
 تعاونكم حسن لكم شاكرين
 
 وتوقيعي اسمي وجود الدراسة، وان هذه في المشاركة قررت وعليه الاستبانة، هذه في الواردة التعليمات جميع على  اطلعتلقد        
 .الدراسة هذه في للمشاركة قبولي على دليل هو
 
 _________________التوقيع                                                                      :المشارك اسم
 
 _________________التوقيع                                                        ياسر قاسم   :الباحث اسم
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Annex (3): Distribution of study cases and control group by studied food intake 
 Total 
N=120 
Case 
N=60 
Control 
N=60 P Value 
n (%) n (%) n (%) 
Fruits 
<2 times a week 15 (12.5) 8 (13.3) 7 (11.7) 
0.082 from 2-4 weekly 75 (62.5) 32 (53.3) 43 (71.7) 
> 4 per weekly 30 (25) 20 (33.3) 10 (16.7) 
Citrus Fruits 
<2 times a week 24 (20) 14 (23.3) 10 (16.7) 
0.141 from 2-4 weekly 38 (31.7) 14 (23.3) 24 (40.0) 
> 4 per weekly 58 (48.3) 32 (53.3) 26 (43.3) 
Melon 
<2 times a week 96 (80) 49 (81.7) 47 (78.3) 
0.648 
from 2-4 weekly 24 (20) 11 (18.3) 13 (21.7) 
Vegetables 
≤4 per week 37 (30.8) 15 (25.0) 22 (36.7) 
0.166 
> 4 per weekly 83 (69.2) 45 (75.0) 38 (63.3) 
Cruciferous 
Vegetables 
<2 times a week 100 (83.3) 43 (71.7) 57 (95.0) 
0.001 
≥ 2 per week 20 (16.7) 17 (28.3) 3 (5.0) 
Fresh Tomato 
<2 times a week 12 (10) 9 (15.0) 3 (5.0) 
0.188 from 2-4 weekly 27 (22.5) 13 (21.7) 14 (23.3) 
> 4 per weekly 81 (67.5) 38 (63.3) 43 (71.7) 
Cocked 
Tomato 
<2 times a week 84 (70) 35 (58.3) 49 (81.7) 
0.005 
from 2-4 weekly 63 (52.5) 25 (41.7) 11 (18.3) 
Carrots 
<2 times a week 109 (90.8) 53 (88.3) 54 (90.0) 
0.769 
≥2per week 13 (10.8) 7 (11.7) 6 (10.0) 
 Milk 
<2 times a week 67 (55.8) 35 (58.3) 32 (53.3) 
0.727 from 2-4 weekly 17 (14.2) 9 (15.0) 8 (13.3) 
> 4 per weekly 36 (30) 16 (26.7) 20 (33.3) 
 Yogurt 
<2 times a week 35 (29.2) 22 (36.7) 13 (21.7) 
0.167 from 2-4 weekly 52 (43.3) 22 (36.7) 30 (50.0) 
> 4 per weekly 33 (27.5) 16 (26.7) 17 (28.3) 
Homemade 
Cheese 
<2 times a week 82 (68.3) 34 (56.7) 48 (80.0) 
0.005 from 2-4 weekly 21 (17.5) 17 (28.3) 4 (6.7) 
> 4 per weekly 17 (14.2) 9 (15.0) 8 (13.3) 
Homemade 
Butter 
<2 times a week 106 (88.3) 51 (85.0) 55 (91.7) 
0.255 
≥2 times per week 14 (11.7) 9 (15.0) 5 (8.3) 
Ice-Cream 
<2 times a week 106 (88.3) 56 (93.3) 50 (83.3) 
0.088 
≥2 times per week 14 (11.7) 4 (6.7) 10 (16.7) 
 Butter Milk 
<2 times a week 103 (85.8) 50 (83.3) 53 (88.3) 
0.655 from 2-4 weekly 11 (9.2) 6 (10.0) 5 (8.3) 
> 4 per weekly 6 (5) 4 (6.7) 2 (3.3) 
Eggs 
<2 times a week 33 (27.5) 12 (20.0) 21 (35.0) 
0.050 
from 2-4 weekly 64 (53.3) 32 (53.3) 32 (53.3) 
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> 4 per weekly 23 (19.2) 16 (26.7) 7 (11.7) 
Red Meat 
<2 times a week 60 (50) 24 (40.0) 36 (60.0) 
0.025 from 2-4 weekly 49 (40.8) 27 (45.0) 22 (36.7) 
> 4 per weekly 11 (9.2) 9 (15.0) 2 (3.3) 
Chicken 
<2 times a week 51 (42.5) 25 (41.7) 26 (43.3) 
0.635 from 2-4 weekly 58 (48.3) 28 (46.7) 30 (50.0) 
> 4 per weekly 11 (9.2) 7 (11.7) 4 (6.7) 
Turkey 
<2 times a week 115 (95.8) 57 (95.0) 58 (96.7) 
0.648 
≥2 times per week 5 (4.2) 3 (5.0) 2 (3.3) 
Processed Meat 
<2 times a week 93 (77.5) 41 (68.3) 52 (86.7) 
0.016 
≥2 times per week 27 (22.5) 19 (31.7) 8 (13.3) 
Hot dogs 
does not take or 
less than once 
monthly 
86 (71.7) 39 (65.0) 47 (78.3) 
0.098 
from 1-3 times 
monthly 
27 (22.5) 15 (25.0) 12 (20.0) 
once weekly 7 (5.8) 6 (10.0) 1 (1.7) 
Fish 
does not take or 
less than once 
monthly 
8 (6.7) 5 (8.3) 3 (5.0) 
0.325 
from 1-3 times 
monthly 
64 (53.3) 
28 (46.7) 36 (60.0) 
once weekly 48 (40) 27 (45.0) 21 (35.0) 
Canned Tuna 
does not take or 
less than once 
monthly 
29 (24.2) 15 (25.0) 14 (23.3) 
0.932 
from 1-3 times 
monthly 
48 (40) 23 (38.3) 25 (41.7) 
once weekly 43 (35.8) 22 (36.7) 21 (35.0) 
 Cola 
<2 times a week 62 (51.7) 32 (53.3) 30 (50.0) 
0.891 from 2-4 weekly 34 (28.3) 17 (28.3) 17 (28.3) 
> 4 per weekly 24 (20) 11 (18.3) 13 (21.7) 
 Coffee 
<2 times a week 21 (17.5) 10 (16.7) 11 (18.3) 
0.931 from 2-4 weekly 23 (19.2) 11 (18.3) 12 (20.0) 
> 4 per weekly 76 (63.3) 39 (65.0) 37 (61.7) 
 Tea 
≤4 a week 9 (7.5) 3 (5.0) 6 (10.0) 
0.298 
> 4 per weekly 111 (92.5) 57 (95.0) 54 (90.0) 
 Green Tea 
≤4 a week 112 (93.3) 55 (91.7) 57 (95.0) 
0.464 
> 4 per weekly 8 (6.7) 5 (8.3) 3 (5.0) 
 Water 
≤3 daily 44 (36.7) 23 (38.3) 21 (35.0) 
0.182 from 4-5 daily 60 (50) 26 (43.3) 34 (56.7) 
from 6+ daily 16 (13.3) 11 (18.3) 5 (8.3) 
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